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SUMMARY
The goal of a Drug Delivery System (DDS) is to provide a localized drug pres-
ence where the medication is needed, while, at the same time, preventing the drug from
affecting other healthy parts of the body. Amongst others, the most advanced solutions
use drugs composed of nano-sized particles for Particulate Drug Delivery Systems (PDDS)
or antibody fragments for Antibody-mediated Drug Delivery Systems (ADDS). Molecular
Communication (MC) is a new paradigm in communication research where the exchange
of information is achieved through the propagation of molecules.
The objective of the proposed research is to develop an analytical framework for the
modeling, performance analysis, and optimization of DDS through the MC paradigm. First,
a fundamental analytical model of the drug particle propagation through the cardiovascu-
lar system is presented, comprised of the blood velocity network, using transmission line
theory, and the drug propagation network, using harmonic matrices theory. The outcomes
of the analytical model are validated by comparing them with physiological measurements
as well as comprehensive simulations of drug propagation in the cardiovascular system us-
ing COMSOL finite-element simulation and kinetic Monte-Carlo simulations. Second, the
MC-PDDS model is developed to take into account the biochemical interactions between
the nanoparticles and the body. The performance and optimization of the MC-PDDS is
studied through delay, path loss, noise, and capacity. Third, the MC-ADDS model is de-
rived to capture the peculiarities of antibody-antigen transport and interactions. The effect
of the shape and electrochemical structure of the ADDS molecules is reflected on the de-
lay, path loss, and noise. The MC-DDS system modeling is shown to be a full-fledged and




Targeted Drug Delivery Systems (DDS) are nowadays under intensive study as they are at
the cutting edge of modern medical therapeutics [1]. In particular, the goal of DDS is to
provide a localized drug presence where the medication is needed, while, at the same time,
preventing the drug from affecting other healthy parts of the body. For this, the design
of a DDS involves the joint optimization of the drug chemical behavior and the transport
process from the point where the drug enters the body until reaching the targeted site.
In a DDS, the drug must be efficiently delivered in the desired concentrations where it
is needed. The understanding of how the drug molecules diffuse in the body and the evolu-
tion of their distribution over time is of primary importance for the design of a DDS. The
delivery of drug molecules can be viewed as a communication mechanism, where the drug
molecules are information carriers, which propagate messages (drug chemical properties)
from the location of transmission (intravascular injection) until the location of reception
(targeted site). We advocate for the Molecular Communication (MC) paradigm [2] as a
straightforward and efficient abstraction of DDS.
The Molecular Communication (MC) paradigm abstracts the propagation of informa-
tion between a sender and a receiver realized through mass transport phenomena, since
information-bearing molecules have to physically cover the distance from one location to
the other. MC is increasingly attracting the interest of the research community working in
the field of nanonetworking [2]. MC is a bio-inspired paradigm that, amongst others, has
been developed by nature for communication among living organisms, such as cells for in-
tracellular and intercellular signaling [3]. In MC, information is exchanged by the release,
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Figure 1. Molecular communication abstraction of PDDS.
1.1 Particulate Drug Delivery Systems
The study of a Particulate Drug Delivery System (PDDS) is especially suited to the MC
abstraction. As shown in Figure 1, PDDS takes advantage of the blood distribution network
for the propagation of drug particles from a location where they are injected into the blood
flow to a targeted site within the reach of the cardiovascular system. The cardiovascular
system is an intricate network of vessels which distribute the blood throughout the body,
while the blood flow is generated by rhythmic contractions of the heart. In particular, the
mass transport phenomena operated by the cardiovascular system for the propagation of the
drug particles are two, namely, diffusion and advection. As a result of diffusion, the drug
particles in suspension in the blood are subject to the Brownian motion spread from a region
of higher concentration to a region of lower concentration. As a result of advection, the
drug particles are subject to translation by the blood flow in the vessels of the cardiovascular
system. The combination of these two phenomena can be interpreted and modeled as an
MC channel. This abstraction should comprise a complete analytical model of the drug
particle propagation through the cardiovascular system. The interactions of nanoparticles
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with the blood, their adhesion and absorption by tissues and biological fluids, should be
reflected by the model with greater accuracy than existing multi-compartmental models [4].
Also, the time-varying characteristics of the blood flow, which significantly affect the drug
propagation, should be considered in the new MC model. The effect of the noise and the
capacity of the MC model of DDS could be studied to evaluate the performance of DDS
from a communication point of view. The MC paradigm has the potential to provide a
highly precise, realistic, and flexible framework for the design and optimization of PDDS.
1.2 Antibody-mediated Drug Delivery Systems
Antibody-mediated Drug Delivery Systems (ADDS) are one of the most advanced thera-
peutic methods [5]. ADDS uses artificial molecules that are constructed from biological
materials to build and engineer drug delivery systems. They are inspired by the naturally
occurring autoimmune mechanisms that enable the human body to diagnose itself and de-
stroy the exact source of the disease, in an adaptive and constructive fashion. The versatility
in engineering ADDS and their attested clinical success open up the possibility to develop
sophisticated therapeutic strategies to effectively target diseases. As shown in Figure 2, the
drug injection of the antibody molecules propagates and diffuses through the network of
blood vessels, where they are also transported through the tissue. Upon entering the tissue,
the antibodies specifically bind to the diseased cells because they express unique antigens
not found in healthy cells and match to the antibody. The binding triggers a therapeutic
effect to the cells through a special case of the ligand-binding process, called the antibody-
antigen mechanism. The MC-ADDS modeling could provide a clearer understanding of
the mode of operation of antibodies, and enable the development of innovative methods to
guide the engineering of verifiable and safe antibody mediated therapies. This includes the
design and engineering of the drug structure, mode of administration, and dosage optimiza-
tion [6].
We propose to use the MC paradigm to model the ADDS while taking into account
3



















Figure 2. Molecular communication abstraction of ADDS.
the unique features of the antibodies and the new possibilities that are offered through
them. Based on the sequential stages of antigen delivery to the target diseased cells, certain
aspects of the MC modeling for PDDS are similar to ADDS. However, the transport and
mechanism of action of ADDS is more complex and advanced than PDDS because of
the complexity in the shape and biochemistry of the antibody and the antigen. In fact, the
efficiency of the ADDS depends on the shape, electric charges, and the ability of the ADDS
molecule to recognize the target antigen. In PDDS, the degrees of freedom in designing the
nanoparticle are limited in terms of shape and surface chemistry due to their size, while in
ADDS, the antibody-antigen recognition mechanism allows for more specific targeting of
the diseased cells by allowing the design of ADDS molecules to bind exactly to a certain
biomolecule. Also, the diffusion parameters of the ADDS molecules in the blood and
through tissues depend significantly on their shape.
MC-ADDS opens up the possibility to optimize the properties of the ADDS to achieve
a desired therapeutic effect, by determining the personalized optimal injection pattern in
terms of frequency, concentration level, and mode of administration, thus maximizing the
safety and success of ADDS and minimizing the costs [7]. The second motivation behind
the use of MC-ADDS modeling, is to understand the physicochemical interactions between
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ADDS and the body, which are more complex than in PDDS. For example, ADDS un-
dergo electrostatic forces within the Extracellular Matrix (ECM) due to negatively charged
proteins [8]. These electric forces significantly affect the intercellular transport, antigen
binding, and the absorption of the ADDS by the cells.
1.3 Organization of the Thesis
The thesis focuses on developing an analytical framework for the modeling, performance
analysis, and optimization of DDS through the MC paradigm. The selection of the MC
paradigm is motivated by a literature survey, contained in Chapter 2, which identifies the
state-of-the-art in modeling DDS from the biomedical engineering field and reviews the
different MC modeling approaches initiated from the communication field that are translat-
able to DDS. Chapter 3 presents as system model of particulate drug delivery systems based
on molecular communication. Chapter 4 contains the molecular communication analysis of
noise and information theoretical capacity in a particulate drug delivery systems. In Chap-
ter 5, the molecular communication modeling is applied to derive the pharmacokinetics
and biodistribution properties of a DDS. In Chapter 6, the molecular communication mod-
eling is tailored to enable the study of antibody-mediated drug delivery systems. Finally,




In this chapter, we review the state-of-the-art in two areas covered by this proposal, namely
MC and DDS. On the one hand, the previous work in MC has focused on diffusion-based
channel and ligand-binding kinetics, in idealized environments. We show here that these
models are not readily applicable to the human body, and need to be extended to account
for realistic propagation environments. On the other hand, the DDS research has addressed
many issues in tracking the time and space evolution of the drug concentration in the body
but lacks in terms of the level of detail and versatility in capturing individual specificities
and the peculiarities of the DDS molecules.
2.1 Molecular Communication
MC is a bio-inspired paradigm that, amongst others, has been developed by nature for
communication among living organisms, such as cells for intracellular and intercellular
signaling [3]. In MC, information is exchanged by the release, the propagation and the
reception of molecules [9]. Due to its inherent bio-compatibility, MC is a competitive
solution to the problem of communication in nanonetworks [10], especially for bio-nano-
medical applications. MC is increasingly attracting the interest of the research community
working in the field of nanonetworking [2]. Targeted DDS has been envisioned as one of
the most important applications of the MC paradigm. In the context of targeted DDS, the
information conveyed by the the particles is the therapeutic action.
The channel model of molecular communication by diffusion has been analyzed theo-
retically in relation to the underlying physical processes [11]. Also, the stochastic effects
in the ligand-receptor binding kinetics have been modeled through a molecular commu-
nication framework [12]. The maximum achievable information rates in diffusion-based
6
molecular communication under the constraints of Brownian motion noise have been de-
rived in [13] using an novel thermodynamic information theoretical framework. Many
different types of MC have been studied so far, which involve either passive transport of
molecules (diffusion-based architectures [14]) or active transport (molecular motors [15],
bacteria chemotaxis [16]).
These existing models rigorously reflect unique channel effects in molecular communi-
cation, but they cannot be directly applied for DDS in the complex human body, because
they assume linear time-invariant channel models for the propagation medium, which is
not reasonable to assume in the cardiovascular system where the blood flow is highly time-
varying, and they suppose a free space geometry, while the molecular communication in the
cardiovascular system is confined to the complex topology of blood vessels. The molecular
communication reception of nanoparticles is also heavily affected by the blood flow that
interferes with the chemical interactions between ligands and receptors [17].
2.2 Targeted Drug Delivery Systems
The so-called multi-compartmental approach [18] are the most successful computational
models of drug propagation for conventional targeted DDS. Multi-compartmental models
consider large portions of the human body as a single compartment, which is supposed to
be homogeneous. The time and space evolution of the drug molecules in one compart-
ment is commonly described through first-order differential equation, and is obtained for
a large timescale in the order of hours. These multi-compartmental models for DDS are
categorized as follows:
• TMDD (Target-Mediated Drug Disposition) [19] [20], which uses first-order linear
differential equations, with a limited number of parameters (around five), and takes
into account non-linearity in the case of saturation. TMDD is empirical.
• PK/PD (Pharmacokinetics and Pharmacodynamics) [21] [22], which is a model that
also takes into non-linearity in case of saturation and of second-order kinetics. The
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parameters of the model are statistically derived from experimental work, and it gives
the pharmacokinetics in the spatial scale of a cell. PK/PD only gives information on
a local level, and does not reflect the global effect of drug injection.
• PBPK (physiologically-based pharmacokinetics) [18] [23], which are based on the
division of the human body in several compartments, each representing an individual
organ. Unike PK/PD, this model gives results on the global level of the body.
The aforementioned models are limited because their parameter values are empirically
obtained. This makes the study of patient variability in drug disposition particularly dif-
ficult. Also, many assumptions simplify the scenario in these models, such as the ones
regarding mixing, time-invariance, and convection. The mixing is assumed perfect in one
organ, the blood convection is assumed constant and uniform in one organ. Also, these
methods focus more on the chemical kinetics than the mass transport.
Another issue with existing DDS models is that they are not easy to optimize. We need
models for which the optimization problems can have an explicit solution, especially given
the high number of parameters that affect the design and propagation of drug nanoparticles.
The existing models are not sufficiently detailed and flexible to study advanced drug de-
livery systems. Nanomedicine-enabled methods such as PDDS require new computational
models where the drug interactions with the body are described with great precision at a
much smaller time and space resolution and in a tractable manner.
The most promising of the aforementioned models, namely PBPK, suffers from many
limitations that make them inapplicable to advancing the current state-of-the-art in nano-
medicine [24] [25]. The issue with the PBPK model is that the diseases that are meant to
be targeted, such as tumors, are highly localized and grow quickly, and this model does
not provide enough spatial and temporal accuracy to assess the efficiency of a DDS. Novel
modeling and optimization approaches are needed for DDS design. The MC paradigm is
well-equipped for achieving a physiologically-based analytical framework for DDS.
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CHAPTER 3
MOLECULAR COMMUNICATION SYSTEM MODEL FOR
PARTICULATE DRUG DELIVERY SYSTEMS
3.1 Motivation and Related Work
Targeted Drug Delivery Systems (DDS) are nowadays under intensive study as they are
at the cutting edge of modern medical therapeutics [1]. In particular, the goal of DDS
is to provide a localized drug presence where the medication is needed, while, at the same
time, preventing the drug from affecting other healthy parts of the body. The most advanced
solutions use drugs composed of micro or nano-sized particles (particulate DDS), which are
able to diffuse into the blood stream to be transported into arteries, veins and capillaries and
to cross barriers that prevent large particles and organisms from escaping the bloodstream.
The transport of drug particles in the human body can be viewed as a communication
system using the Molecular Communication (MC) paradigm where information is con-
veyed through the transport of molecules. The MC paradigm will give us a clear under-
standing of how the drug particles diffuse in the body and the evolution of their distribution
over time, which is of primary importance for the design of a particulate DDS. In the past
literature, statistical modeling methods, such as the first reaction method based on dynamic
Monte Carlo [26,27], have been often used to solve for this purpose. In this chapter, we
proposed an analytical approach based on the abstraction of a particulate DDSs as a com-
munication mechanism, where the drug particles are information carriers, which propagate
messages (drug chemical properties) from the location of transmission (intravascular injec-
tion) until the location of reception (targeted site).
Targeted DDS has been envisioned as one of the most important applications of the
Molecular Communication (MC) paradigm [2]. MC abstracts the propagation of informa-
tion between a sender and a receiver realized through mass transport phenomena. In the
context of targeted DDS, the information conveyed by the the particles is the therapeutic
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action. MC is increasingly attracting the interest of the research community working in
the field of nanonetworking [2]. MC is a bio-inspired paradigm that, amongst others, has
been developed by nature for communication among living organisms, such as cells for in-
tracellular and intercellular signaling [3]. In MC, information is exchanged by the release,
the propagation and the reception of molecules [9]. Due to its inherent bio-compatibility,
MC is a competitive solution to the problem of communication in nanonetworks [10], es-
pecially for bio-nano-medical applications. Many different types of MC have been stud-
ied so far, which involve either passive transport of molecules (diffusion-based architec-
tures [14] [28]) or active transport (molecular motors [15], bacteria chemotaxis [16]). The
MC paradigm can pave the way for new approaches to the analysis of immune system at-
tacks from a security and safety perspective in analogy with telecommunication security
techniques.
A particulate Drug Delivery System (DDS) takes advantage of the blood distribution
network for the propagation of drug particles from a location where they are injected into
the blood flow to a targeted site within the reach of the cardiovascular system. The mass
transport phenomena operated by the cardiovascular system for the propagation of the drug
particles are two, namely, advection and diffusion. As a consequence of advection, the
drug particles are subject to their translation while in suspension in the blood, which flows
at different velocities in different locations of the cardiovascular system. The blood veloc-
ity profile follows the laws of fluid dynamics and, in particular, the Navier-Stokes equa-
tion [29]. On top of this, as a result of diffusion, the drug particles are subject to the
Brownian motion spread in the blood from a region of higher concentration to a region of
lower concentration. This is interpreted by the laws of particle diffusion and, in particu-
lar, by the diffusion-advection equation [26]. In this chapter, we realized the molecular
communication abstraction of a particulate DDS by developing a MC channel model of the
drug particle propagation through the cardiovascular system. For this, we identified two
separate contributions within the model, namely, the cardiovascular network model and the
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drug propagation network model.
The cardiovascular network model is developed in this chapter as a solution to the
Navier-Stokes equation [29] in the cardiovascular system, and it is based on the application
of the transmission line theory [30]. We have restricted our model of the cardiovascular net-
work to the blood arteries, which are the network of blood vessels that provide organs and
tissues with oxygen and nutrients, because it is the best medical administration to provide
targeted drug delivery to these organs. Our objective is to administer a drug dose to a target
location in the extremity. Systemic arteries are the best candidate route of administration
for targeted drug delivery systems because they allow delivering a localized drug dose to
the periphery without affecting healthy organs and tissues [31]. On the contrary, veins are
more appropriate in the case when the drug must be evenly distributed to the extremities of
the cardiovascular network. By mapping the fluidic parameters of each artery to electrical
circuit components, the cardiovascular network model allows to analytically compute the
blood velocity profile in every artery of the cardiovascular system given the blood flow in-
put from the heart. A similar approach has been suggested in [30], where, differently from
our work, a bulk section of the arterial system is modeled with one circuit component and
does not allow obtaining the blood velocity profile at every possible location. In [32], a
complete fluid dynamic analysis of a pressure pulse propagation in the cardiovascular sys-
tem is performed, but without the flexibility and clarity of a circuit analogue of the blood
flow dynamics in the transmission line model we developed. In [33], a transmission line
model is developed which takes into account only the blood dynamics in the large systemic
artery tree, while our model covers in detail both large and small artery trees. In [34], the
lumped model of any artery is developed, but without taking into account their bifurcations
and the transmission line network solution of an artery tree.
The drug propagation network model is developed in this chapter as a solution to the
advection-diffusion equation [26], and it stems from the knowledge of the blood velocity
profile computed through the cardiovascular network model. Through the application of the
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Harmonic Transfer Matrix (HTM) theory [35] to the drug particle transport in the arteries
and their bifurcations, the drug propagation network allows the analytical expression of the
drug delivery rate at the targeted site given the drug location of injection and injection rate
profile. The derived model takes into account also the individual specificities in the physio-
logical parameters of the cardiovascular system, such as the compliance of the arteries, the
heartbeat rate profile and the heartbeat stroke volume. Molecular mass transport over a net-
work has been very recently approached from the point of view of complex system theory
in [26]. While this method takes into account the time-variance of the flow, the algorithm
couples a graph-based approach and numerical resolution of partial-differential equations
for every vessel, which are not required in our HTM-based approach. Such method implies
a high computation and memory cost. Also, this model does not yield analytical expres-
sions that can be of practical use to solve problems such as the optimization of the drug
delivery. The rest of this chapter is organized as follows. In Sec. 3.2 the main processes
that compose a particulate DDS and their abstractions as the components of an MC system
are introduced, together with the main objective of this work. In Sec. 3.3, the scheme of the
MC channel model of a particulate DDS is detailed into two main contributions, namely,
the cardiovascular network model and the drug propagation network model. Sec. 3.4 details
the cardiovascular network model, while Sec. 3.5 describes the drug propagation network
model. Sec. 3.6 analyzes the numerical results stemming from the proposed solution. Fi-
nally, Sec. 3.7 concludes the chapter.
3.2 Molecular Communication Abstraction of a Particulate DDS
A particulate Drug Delivery System (DDS) takes advantage of the blood circulation in the
cardiovascular system for the propagation of drug particles from a location where they are
injected into the blood flow until they reach a targeted site. We describe a particulate DDS
as composed of three main processes, namely, Injection, Propagation, and Delivery, as
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Figure 3. Graphical sketch of the main processes in a particulate DDS and their MC abstractions.
of information through the emission of particles from a Transmitter, their propagation
through mass transport phenomena in the Channel, and their reception at the destination
by a Receiver. We define the particulate DDS processes and their MC abstractions as
follows:
• The Injection process is the introduction of the drug particles in the blood flowing
in the cardiovascular system at a predefined location of injection I. The injection
is performed according to a particle injection rate x(t) defined as the first derivative
with respect to the volume v in the number of injected particles in the location of
injection as the function of the time t:
x(t) =
∂ {# injected particles} (t)
∂v
. (1)
We abstract the injection process as the MC Transmitter where I is the transmitter
location and x(t) is the transmitted molecular signal.
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• The Propagation process is the spread of the drug particles throughout the cardiovas-
cular system. The cardiovascular system shows a topology of interconnected blood
vessels where the blood flows due to the heart pumping action, which is expressed
as the cardiac input qin(t), defined as the blood flow input to the cardiovascular car-
diovascular system as function of the time t. Drug particles propagate through the
blood vessels according to the superposition of two physical phenomena, namely,
advection and diffusion. Advection is the transport of particles suspended in a fluid
due to the fluid’s bulk motion. Diffusion is the spontaneous spread of particles sus-
pended in a fluid from a space region where they are in a higher concentration to
another region where they are in a lower concentration. We abstract the propagation
process as the MC Channel, where the transmitted molecular signal is propagated
via advection-diffusion through the blood flow in the cardiovascular system.
• The Delivery process is the arrival of the drug particles at the targeted site O, where
they are expected to perform their healing action. The drug delivery process is char-
acterized by the particle delivery rate y(t) at the targeted site, defined as the first
derivative with respect to the volume v in the number of particles present at the tar-
geted site as function of the time t:
y(t) =
∂ {# particles at targeted site} (t)
∂v
. (2)
We abstract the delivery process as the MC Receiver where O is the receiver location
and y(t) is the received molecular signal.
One of the main objectives in the study of a particulate DDS is to develop a model to
analytically compute the particle delivery rate y(t) at the targeted site as function of the
time t from the knowledge of the location of injection I, the particle injection rate x(t), the
cardiac input qin(t) and the targeted site O. This is expressed as follows:
y(t) = f (I, x(t), qin(t),O) , (3)
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where the function f (.) represents the analytical model. We abstract this objective as the
modeling of the MC channel between the MC transmitter located at I and the MC receiver
located at O, where the input transmitted molecular signal x(t) is propagated by advection
and diffusion in the blood flowing through the cardiovascular system as function of the
cardiac input qin(t). The output of this MC channel is the received molecular signal y(t).
The outcome of the model expressed in (2) through the MC abstraction is twofold:
• To study optimization techniques for particulate DDSs which could allow a careful
selection of the location of injection I and a definition of the particle injection rate
x(t) as function of the time t with the goal of obtaining a desired particle delivery rate
y(t) as function of the time t at a targeted site O, while minimizing the drug spread in
the rest of the cardiovascular system [1].
• To develop a novel MC technique to realize Intra-Body Communication (IBC) net-
works [36] by modulating at the transmitter the injection of particles in the blood
according to the signal to be transmitted, and, upon their propagation through the
cardiovascular system, by demodulating the received signal from the delivery rate of
incoming particles at the receiver.
3.3 Scheme of the MC Channel Model of a Particulate DDS
The MC channel model of a particulate DDS developed in this chapter is divided into two
main contributions, namely, the Cardiovascular Network Model and the Drug Propa-
gation Network Model, as shown in Fig. 4. These two contributions are summarized as
follows:
• The Cardiovascular Network Model is developed as a solution to the Navier-Stokes
equation [29], which relates the blood velocity vector ul(r, t), function of the radial

















Figure 4. Scheme of the MC channel model of a particulate DDS with the two contributions.





+ ul(r, t) · ∇ul(r, t)
)
= −∇p(t) (4)
+ µ∇2ul(r, t) + f ,
where ρ is the blood density, which we assume homogeneous, ∇ is the Nabla vector
differential operator, µ is the blood viscosity, and f represents the contribution of
blood vessel wall properties [37]. As detailed in Sec. 3.4, the cardiovascular network
model allows to compute the blood velocity ul(r, t) as function of the time t in every
artery l of the cardiovascular system CV from the knowledge of the cardiac input
qin(t), expressed as follows:
qin(t)
Cardiovascular Network Model
−−−−−−−−−−−−−−−−−−−−→ {ul(r, t)|l ∈ CV} , (5)
where qin(t) is the blood flow input to the cardiovascular system, {.} is the set symbol
and CV denotes the set of all the arteries included in the cardiovascular system. As
explained in Sec. 3.4, the cardiovascular network model is developed through the ap-
plication of the transmission line theory [30] to the modeling of the interconnection
of the arteries in the cardiovascular network.
• The Drug Propagation Network Model is developed as a solution to the advection-
diffusion equation [38], which relates the drug concentration c(t) in every location of
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the cardiovascular system to the blood velocity vector ul(r, t) as functions of the time
t. It is expressed as follows:
∂c(t)
∂t
= −∇. [−D∇c(t) + ul(r, t)c(t)] , (6)
where ∇ is the Nabla vector differential operator, and D is the particle diffusion co-
efficient. As detailed in Sec. 3.5, the drug propagation network model allows to
compute the particle delivery rate y(t) at the targeted site as function of the time t
from the knowledge of the location of injection I, the particle injection rate x(t), the
blood velocity ul(r, t) as function of the time t in every artery l of the cardiovascular
system CV , and the targeted site O, expressed as follows:





where {.} is the set symbol and CV denotes all the arteries included in the cardio-
vascular system. The drug propagation network model is developed by applying the
Harmonic Transfer Matrix (HTM) theory [35] to express the transfer function of
each artery and bifurcation in the cardiovascular system CV , as explained in Sec. 3.5.
The MC channel model, composed by the two aforementioned contributions, allows to
find the analytical solution to the objective expressed in (2) by using the particulate DDS
MC abstraction. The cardiovascular network and drug propagation network models are
detailed in Sec. 3.4 and 3.5, respectively.
3.4 Cardiovascular Network Model
The cardiovascular network model allows to compute for every artery l the blood velocity
ul(r, t) as function of the distance r from the blood vessel axis and the time t, and it stems
from the closed-form solutions to the Navier-Stokes equation (4) applied to the cardiovas-
cular system. As shown in Fig. 5, the cardiovascular network model is composed of the
following elements:
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• The Cardiac Input Qin(ωk), which is the flow Qin(ωk) exerted by the heart as func-
tions of the heartbeat frequency component ωk. The blood pressure is defined as the
force induced by the blood on the walls of a blood vessel, while the blood flow is
defined as the quantity of blood traversing the cross section of a blood vessel per unit
time. The computation of Qin(ωk) is detailed in Sec. 3.4.1.
• The Small Arteries Model. Small arteries are defined as the systemic circulation
vessel with a radius comprised between 0.05mm and 2mm. They have muscular walls
and deliver blood to capillaries. This model is developed in Sec. 3.4.2 and gives the
transfer matrix and load impedance for a small artery l.
• The Large Arteries Model. Large arteries are defined as the systemic circulation
vessels with a radius larger than 2mm. They have elastic walls and branch ultimately
into small arteries. Their model is developed in Sec. 3.4.3 and also yields the transfer
matrix and load impedance for a large artery l.
• The General Transfer Matrix and Load Impedance T(ωk). It characterizes the
cardiovascular network between the heart and any small or large artery l and it is
computed from the aforementioned elements by applying the transmission line the-
ory [30]. We express T(ωk) as a 2×2 matrix with elements A(ωk), B(ωk), C(ωk), and
D(ωk) in Sec. 3.4.4.
• The Blood Velocity. The output of the cardiovascular network is the blood velocity
ul(r, t) in a large or a small artery l. We suppose that it is homogeneous along the
longitude of the artery and that it only depends on time variable t and the radial
coordinate r in the artery. We find in Sec. 3.4.5 a final relationship that gives the
blood velocity ul(r, t) of any artery l of the cardiovascular system CV from the cardiac



























Figure 5. Path between the cardiac input and the small artery l.
where Qin(ωk) is the cardiac input, Zl(ωk) is the load impedance of the artery l, and
C(ωk) and D(ωk) are the first and second elements of the second row of the trans-
fer matrix T(ωk) representing the cardiovascular network between the heart and the
artery l sampled at angular frequency ωk respectively.
3.4.1 Cardiac Input
The cardiac input Qin(ωk) is the blood flow ejected by the heart in the cardiovascular system
as functions of the heartbeat frequency component ωk. Qin(ωk) is considered to be the
Fourier coefficients of the blood flow qin(t) taken from clinical measurements provided
in [37] and performed by using Magnetic Resonance (MR) on a set of human individuals.
By exploiting the periodicity of the cardiac input, we compute the Fourier coefficients [39]







qin(t)e− jωk dt . (9)
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3.4.2 Small Arteries Model
3.4.2.1 Load Impedance of a Small Artery
The modeling of a small artery l as an electrical component with a load impedance Zl(ωk) is
explained in the following. The load impedance Zl(ωk) is calculated recursively according
to the algorithm described in Algorithm 1. The harmonic impedance Z′l (ωk) of the sister
branch is calculated similarly.
Small arteries possess the following properties:
• The scaling parameters α and β, which are scaling parameters that relate the radii of
the two bifurcating arteries rl at the left and r′l at the right to the radius rl−1 of their
parent artery l − 1 (rl = αrl−1 and r′l = βrl−1)
The tree is terminated when the radius is no larger than a minimal radius rmin. The
tree representation for the renal artery is given in Fig. 18.
• The length `l, which is proportional to the radius rl of the small artery. Since, the
tapering is no longer significant in small arteries, it is possible to consider small
arteries as cylinders. It has been observed from measurements that the length-radius
ratio lrr is constant for small arteries. In fact the length of a small artery l can be
expressed approximately in function of its radius rl as follows:
`l = lrrrl = (50 ± 10) rl . (10)
• The volume compliance cl, which is supposed to be similar to the volume compliance
for large arteries (20).
Due to the different mechanical and geometric properties between large and small ar-
teries, we use a different transmission line model for small arteries.
According to [40], the harmonic pressure Pl(ωk) and the harmonic flow Ql(ωk) in a
small artery l can be related by a load impedance Zl(ωk) as follows:
Pl(ωk) = Zl(ωk)Ql(ωk) . (11)
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Eq. (11) is similar to Ohm’s law [41] if pressure is seen as voltage and flow as current.
More importantly, the harmonic impedance at the inlet of the small artery Zl(ωk) and the
harmonic impedance at the outlet of the small artery Zoutl (ωk) are related by the following
relationship [40]:
Zl(ωk) =
jτl(ωk) sin (τl(ωk)) /`l + Zoutl (ωk) cos (τl(ωk))
















where rl is the small artery radius, `l is the small artery length, lrr is the length-to-radius
ratio, ρ is the blood density, µ is the blood viscosity, υ = µ/ρ is the blood kinematic
viscosity, cl is the small artery volume compliance, j is the imaginary unit, J0 and J1 are
the Bessel function of the first kind and, respectively, zero and first order [42].




+ Zoutl (ωk) . (14)
The conservation of flow at the bifurcation, and continuity of pressure justify the mod-
eling of bifurcations as the branching of perfectly conducting wires in the electric analogue
of blood flow and pressure, and allow the application of Kirchhoff’s current and voltage
laws [43]. The harmonic impedance at the output Zoutl (ωk) can be related to the harmonic
impedance at the daughter small artery l + 1 Zl+1(ωk) and the harmonic impedance of its










The tree of small arteries is truncated when the radius rl is no larger than rmin. The
harmonic impedance of a small artery l such as rl < rmin is taken to be zero. With this
condition, we can compute the load impedance Zl(ωk) of a small artery l according to the
recursive function in Algorithm 1, where f (ZOut, r), implementing the expression defined
in (12), returns the impedance ZIn given the output impedance ZOut and the radius r.
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Algorithm 1 Recursive computation of the load impedance of a small artery.
1: Global alpha, beta, rMin . Parameters
2: function ImpedanceSmall(r)
3: if r ≤ rMin then
4: ZR← ImpedanceS mall(beta ∗ r) . ZR: Impedance of the right daughter artery
5: ZL← ImpedanceS mall(alpha ∗ r) . ZL: Impedance of the left daughter artery
6: ZOut ← 1/(1/ZR + 1/ZL)














Figure 6. Transmission line model for a tree of small arteries.
3.4.2.2 Small Artery Transfer Matrix
Here, we find a transfer matrix Tl(ωk) that relates the harmonic flow and pressure [Pl(ωk) Ql(ωk)]′
in a small artery l located in a tree of small arteries to the flow and pressure at the root il of
the tree of small arteries
[
Pil(ωk) Qil(ωk)
]′ (cf. Fig. 7).
By calculating the harmonic impedance at the root artery Zil(ωk) the harmonic impedance
at the small artery l Zl(ωk) and at its sister small artery Zl′(ωk), we can represent the tree
of small arteries by the two-port network in Fig. 6. Using Kirchhoff’s circuit laws, we
find a linear system involving the input pressure Pil(ωk), the input flow Qil(ωk), the output
pressure Pl(ωk), and the output flow Ql(ωk). Hence, the flow and pressure in a small artery
l and the root of the tree of small arteries i are related by the following matrix relationship






Interface between large arteries

























where Sl = (...,m, ..., l − 1, l) is the sequence of all small arteries carrying blood from the




]′ is the harmonic flow and pressure at the root of the tree of
small arteries il, and ∆Zm−1(ωk) is the impedance between the inlets the small arteries m
and m − 1 which is computed as in the following,




Zm(ωk), Zm′(ωk), and Zm−1(ωk) are, respectively the harmonic impedance of the small artery





















Figure 9. A large artery m as an axisymmetric tube with tapering radius in the (r,z) plan.
3.4.3 Large Arteries Model
The objective of this section is to present an expression of the transfer matrix Tl(ωk) for
a large artery l and an algorithm to calculate the load impedance Zl(ωk) for a large artery
located in the cardiovascular system.
3.4.3.1 Large Artery Transfer Matrix
The transfer matrix Tl(ωk) for a large artery l depends on its geometric dimensions and
physiological parameters of the artery, which are as follows:
• Radius tapering. A large artery l is considered as an axisymmetric tube with decreas-
ing radius as illustrated in Fig. 9 and length `l. The inlet of the large artery l has a






l . The numerical
values for rtopl ,r
bot
l , and `l are found from anatomical measurements (cf. Table 1).We
consider z as the longitude coordinate along the axis of the large artery, and rm(z)
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as the radial distance of the tube surface to the axis at z, the radius rl(z) decreases
exponentially from rtopl at z = 0 to r
bot
m at z = `l, as follows:
rl(z) = r
top
l exp(−klz) , (19)




• The volume compliance, which quantifies the tendency of the artery walls to yield to
pressure and other external forces. Using statistical studies of physiological measure-
ments [37], the volume compliance cl can be estimated by the following equation:
cl(z) =
πrl2(z)
k1 exp(−k2rl(z)) + k3
, (20)
where k1 = 1.34 × 107g/(s2.cm), k2 = 22.53cm−1, and k3 = 5.77 × 105g/(s2.cm).
The blood flow in a large artery is assumed to be laminar, viscous, and incompress-
ible, and that pressure is constant over the cross-section of the large artery. Starting from
the Navier-Stokes equation (4), equating the variance of the flow in a large artery with the
volume absorbed by the large artery due to its compliance, we get a system of coupled dif-





















This system is governed by differential equations which resemble the Telegrapher’s
equations. A Telegrapher’s equation have an electrical circuit analogue as illustrated in


















the admittance per unit length G
′
l = 0, and are expressed as function of the physiologi-
cal parameters previously defined, with rl = rl(z = `l). Stemming from these electrical
components, two important parameters are hence defined for a large artery segment l:












• The characteristic impedance Z◦l (ωk), defined as the impedance that the transmission











By applying the two-port network circuit analysis [41], the Fourier coefficients of the pres-
sure Pl(ωk) and flow Ql(ωk) in the large artery segment l can be related to the Fourier










where Al(ωk), Bl(ωk), Cl(ωk), and Dl(ωk) are the elements of the transfer matrix Tl(ωk) of
the large artery l, defined as [46]:
Al(ωk) = cosh (γl(ωk)`l)











































Figure 11. A tree of large arteries as branching transmission lines.
where γl(ωk) is the propagation coefficient of large artery segment l, Z◦l (ωk) is the charac-
teristic impedance of large artery segment l, and `l is its length.
3.4.3.2 Load Impedance of a Large Artery
The load impedance of a large artery Zl(ωk) is a measure of the opposition experienced by
the blood flow at the inlet of a large artery l. It depends on the topology of all large arteries
that branch out from large artery l and their geometric dimensions. Large arteries are
arranged in a tree-like structure. The arteries grow out from the aorta, the systemic artery
originating at the heart, and branch out to reach the peripheral body tissues and organs.
Measurements of the position of arteries and the points of bifurcations are available from
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anatomy books [47], and are presented in Table 1. The large arteries are ended by a tree of
small arteries which are presented in 3.4.2.
Fig. 10 illustrates the topology of the tree of large arteries branching out from a large
artery l. As shown in Fig. 11, the tree of large arteries is terminated by trees of small arteries
with load impedance Zil′+1(ωk), Zil′+2(ωk), Zil+1(ωk), etc. which are calculated according to
the algorithm presented in Sec. 3.4.2.1.
Using transmission line theory [45], it is possible to express the load impedance of the
large artery l in function of the load impedance at its outlet, which is denoted Zoutl (ωk).
Zl(ωk) = Z◦l (ωk)
Zoutl (ωk) + Z
◦
l (ωk) tanh (γl(ωk)`l)
Z◦l (ωk) + Z
out
l (ωk) tanh (γl(ωk)`l) ,
(28)
where Z◦l (ωk) and γl(ωk) are respectively the propagation coefficient and characteristic
impedance for the large artery l as found in (23) and (24). If the large artery l branches out











Otherwise, if the large artery l is terminated by a tree of small arteries, the load impedance
at the outlet of large artery l is exactly the load impedance of interface with small arteries
Zil(ωk).









where l + 1 and l′ + 1 are the indexes of the small arteries braching out if the large artery l.
We can describe the procedure required to get the load impedance Zl(ωk) of the large
artery l by the recursive algorithm in Algorithm 2 by defining:
• f : (ZOut, L,R)→ ZIn as the function that returns the load impedance ZIn of a large
artery with radius R and length L, and the load impedance at its outlet ZOut.
• r(l), rBot(l) and l(i) as the functions that return the radius at the top, the radius at the
bottom, and the length of the large artery i, respectively.
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Algorithm 2 Recursive computation of the load impedance for a large artery.
1: Global alpha, beta . Parameters
2: function ImpedanceLarge(i)
3: if r ≤ 2e − 3 then . Large artery branches
4: iR← IdR(i)
5: iL← IdL(i)
6: ZR← f (ImpedanceLarge(iR), l(iR), r(iR))
7: ZL← f (ImpedanceLarge(iL), l(iL), r(iL))
8: ZOut ← 1/(1/ZR + 1/ZL)
9: else . Small artery interface
10: ZR← ImpedanceS mall(alpha ∗ r(i))
11: ZL← ImpedanceS mall(beta ∗ r(i))





















Figure 12. Overview of the transmission line network of the cardiovascular system.
• IdR(i) and IdL(i) as the functions that return the index of the large artery branching
out of the artery i to the right and to the left, respectively.
These functions are based on the data provided in Table 1 and the topology of the large
arteries in Fig. 21.
We present in this section the expression of the transfer matrix T(ωk). This transfer
matrix represents the propagation effect of the cardiovascular network between the heart
where the cardiac input Qin(ωk) is pumped and an artery l experiencing a blood flow Ql(ωk)
and a pressure Pl(ωk).
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3.4.4 General Transfer Matrix and Load Impedance
The part of the cardiovascular vascular system between the heart and the artery l in the
direction of the flow is called here the pre-l network, and the part between the artery l and
the venous system in the direction of the flow is called the post-l network as illustrated in
Fig. 12.
• The pre-l network is characterized by a a transfer matrix T(ωk) that imposes a lin-
ear relationship between the cardiac input Qin(ωk), the pressure exerted by the heart








• The post-l network is characterized by a load impedance Zl(ωk) that imposes a rela-
tionship between the blood flow Ql(ωk) and the pressure Pl(ωk) in artery l as follows:
Pl(ωk) = Zl(ωk)Ql(ωk) . (33)
We have previously presentend the algorithms that return the load impedance Zl(ωk) for
a small artery l in Sec. 3.4.2.1 and for a large artery l in Sec. 3.4.3.2.
By cascading the transfer matrices [45] of all large arteries m carrying blood from the
heart to the large artery l and the transfer matrices of large artery branches along this path
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Figure 13. Path between the cardiac input and a small artery l.
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where Ll = (...,m, ..., l − 1, l) is the sequence of all large arteries carrying blood from the
heart to the artery l, A(ωk), B(ωk), C(ωk), and D(ωk) are the matrix elements of the transfer
matrix Tm(ωk) of an artery m (27), T1(ωk) is the transfer matrix of the aorta (the large artery
directly connected to the heart), Tl(ωk) is the transfer matrix of the artery l, whether it is a
small artery (17) or a large artery (27), and Zm′(ωk) is the load impedance of the artery m′
parallel to m (See Fig. 13).














where Sil = (...,m, ..., il) is the sequence of all large arteries carrying blood from the heart
to the interface il of the tree of small arteries to which l belongs.
3.4.5 Blood Velocity
The objective of this section is to present the expression of the blood velocity ul(r, t)
given the cardiac input Qin(ωk), the transfer matrix T(ωk), and the load impedance Zl(ωk)
which were expressed in the preceding section.By connecting a pre-l network with load
impedance Zl(ωk) to the post-l network with transfer matrix T(ωk), we enforce the equa-
tions (31) and (33), and we collapse the two-port network into a one-port network. There-
fore, we eliminate the pressures Pin(ωk) and Pl(ωk), and the harmonic flow Q(ωk)l in the





where C(ωk) and D(ωk) are the first and second elements of the second row of the transfer
matrix representing the cardiovascular network between the heart and the artery l sampled
at angular frequency ωk respectively, and Zl(ωk) is the harmonic impedance of the artery l.
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Figure 14. Drug propagation network model.
vessel, and the time t from the periodic blood flow in the time-domain ql(t) by assuming a








Ql(ωk)e jωkt . (37)
3.5 Drug Propagation Network Model
The drug propagation network model allows to compute the drug delivery rate y(t) at the
targeted site as function of the time t from the knowledge of the blood velocity ul(r, t) in
every artery l of the cardiovascular system, function of the distance r from the artery axis
and the time t, computed through the cardiovascular network model detailed in Sec. 3.4.
The drug propagation network model stems from the solutions to the advection-diffusion
equation expressed in (6), and it is composed of the following elements:
• Artery Link Models. An artery link is defined as the arterial blood vessel segment
which connects two adjacent bifurcations. The artery link models are derived from
the solution to the General Taylor Dispersion equation [48], which is a simplification
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of the advection-diffusion equation (6) in case of advection in a cylindrical pipe.
Each artery link l model is expressed by a Linear Periodically Time-Varying (LPTV)
impulse response hlinkl (t, t
′) as function as function of the time variables t and t′, as
detailed in Sec. 3.5.1.
• Junction Node Models. A junction node is defined as the arterial location where an
incoming blood flow is split into two outgoing diverging flows. The junction node
models are derived from the principle of mass conservation [49] in fluid mechanics,
and each junction node n model is expressed by an LPTV impulse response hn(t, t′),
as detailed in Sec. 3.5.2.
• Bifurcation Node Models. A bifurcation node is defined as the venal location where
two incoming blood flows are joined into one single flow. Similarly, the bifurca-
tion node n is characterized by an LPTV impulse response hn(t, t′), as detailed in
Sec. 3.5.3.
From the knowledge of the location of injection I and the targeted site O, the Drug Propa-
gation Network Model is expressed by a LPTV impulse response hI,O(t, t′) as function of
the time variables t and t′, through which we compute the drug delivery rate y(t) given the




hI,O(t, t′)x(t′) dt′ . (38)
In Sec. 3.5.4 we detail the procedure to compute the expression of the LPTV impulse
response hI,O(t, t′), function of the time t and the periodic time variable t′, by applying
the Harmonic Transfer Matrix (HTM) theory [35] to the artery link and bifurcation node
models.
3.5.1 Artery Link Models
The model of the artery link l, as illustrated in Fig. 15, corresponds to the relation between
the drug delivery rate yl(t) at the output of the artery link and a drug injection rate xl(t) at
34
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Figure 15. A segment of a blood vessel modeled as an artery link.
the input of the artery link l, functions of the time t. This model is expressed through the
LPTV impulse response hlinkl (t, t






The LPTV impulse response hlinkl (t, t
′), function of the time variables t and t′, corresponds
to the the drug particle concentration cl(z, t) at the artery link longitudinal coordinate z = `l
when the drug injection rate xl(t) at the input of the artery link l is equal to a Dirac delta
δ(t − t′) centered at time t′. This is expressed as follows:
hlinkl (t, t
′) = cl(`l, t)|xl(t)=δ(z)δ(t−t′) , (40)
where `l is the length of the artery link l.
The drug particle concentration cl(`l, t) is computed through the inhomogeneous advection-
diffusion equation [38], simplified into the inhomogeneous General Taylor Dispersion equa-
tion [48], since in the artery link the drug particles are subject to advection in a cylindrical
pipe.
The inhomogeneous General Taylor Dispersion equation when the input drug injection
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= δ(z)δ(t − t′) (41)




where cl(z, t) is the drug particle concentration at longitudinal coordinate z in the artery link






rul(r, t)dr , (42)
where ul(r, t) is the blood velocity at the output of the artery l as function of the distance r
from the artery axis and the time t. De f fl (t) is the effective diffusivity [48] in the artery link
l, expressed as follows:




































ūl(t)ul(r, t)dr , (43)
where rl is the radius of the artery link, and D is the diffusion coefficient [50] of the drug





where KB is the Boltzmann’s constant, Tp is the blood absolute temperature, η is the intrin-
sic viscosity of the particle, which depends on the geometry of the drug particles, and a is
the radius of the drug particles.
To obtain the expression of the drug particle concentration cl(`l, t), we apply the Fourier
transform [51] F {·} with respect to the variable z, which is the longitudinal coordinate in
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the artery, to both terms of the advection-diffusion equation (41), which results in
∂
∂t
F {cl(z, t)} + 2iπξūl(t)F {cl(z, t)} = δ(t − t′) , (45)
+4π2ξ2De f fl (t)F {cl(z, t)}
where ξ is the frequency variable along the artery link longitudinal coordinate z. Using
Green’s method for solving inhomogeneous differential equations [52], we obtain






ξ2 + 2iπξµl(t, t′)
)
U(t − t′) , (46)
where U(·) is the Heaviside step function [53], and where µl(t, t′) corresponds to the particle
displacement as function of the time variables t and t′. It depends on the average cross-





and σl(t, t′) corresponds to the particles spread as function of the time variables t and t′. It







De f fl (τ)dτ
∣∣∣∣∣∣ . (48)
Finally, the expression of the LPTV impulse response hlinkl (t, t
′) is obtained through the
inverse Fourier transform [51] of (46) computed at the artery link longitudinal coordinate














where µl(t, t′) is given by (47), σ2l (t, t
′) is given by (48), and `l is the length of the artery
link l.
3.5.2 Junction Node Model
The model of a junction node n, as illustrated in Fig. 16, corresponds to the relation between
the drug delivery rates yn(t) at the output branch of the junction node n and a drug injection
37
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Figure 16. A blood vessel junction modeled as a cardiovascular network node.
rate xn(t) at the input of the bifurcation node n, functions of the time t. This model is
expressed through the LPTV impulse response hnoden (t, t
′), function of the time variables t






To compute the LPTV impulse response hnoden (t, t
′), function of the time variables t and
t′, we assume that in a junction node the propagation of the drug particles is given mainly
by their advection in the blood flows, while the contribution of their diffusion is negligible.
Under this assumption, the relation between drug delivery rate yn(t) of the junction node n
and a drug injection rate xn(t) at the input of the bifurcation node n, functions of the time t
is computed through the the principle of mass conservation [49] in fluid mechanics, which





where n′ is the index of the sister of the input branch n, ūn(t) and ūn′(t) are the average
cross-sectional blood velocities at the input branches indexed by n and n′, respectively. As
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Figure 17. A blood vessel bifurcation modeled as a cardiovascular network node.
expression for the LPTV impulse response hnoden (t, t







where δ(t) is the Dirac delta time function, n is the index of the junction node input branch,
and n′ is the index of the sister of the input branch n.
3.5.3 Bifurcation Node Model
The model of a bifurcation node n, as illustrated in Fig. 17, corresponds to the relation
between the drug delivery rates yn(t) at the output branch of the junction node n and a drug
injection rate xn(t) at the input of the bifurcation node n, functions of the time t. Similarly,
this model is characterized by an LPTV impulse response hnoden (t, t
′), function of the time
variables t and t′, as follows:
hnoden (t, t
′) = δ(t) , (53)
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This relationship stems from the fact that the concentration is continuous in a bifurca-
tion node.
3.5.4 LPTV Impulse Response of the Drug Propagation Network Model
The LPTV impulse response hI,O(t, t′) of the drug propagation network model having lo-
cation of injection I and the targeted site O, as function of the time variables t and t′, is




hk(t − t′)e jkω0(t−t
′) , (54)
where ω0 is the angular heartbeat frequency, and each Fourier coefficient hk(τ) is com-











e jnω0τ , (55)





denotes the element of the equivalent HTM HI,O(s) of the drug propagation network model
having k + n-th row and n-th column indexes. The equivalent HTM HI,O(s) of the drug
propagation network model is computed by applying the HTM theory to the LPTV im-
pulse response hlinkl (t, t
′) and hnoden (t, t
′) of the artery link and the bifurcation node models,
respectively. This is achieved by considering that both hlinkl (t, t
′) and hnoden (t, t
′) are periodic
with period T , which is the heartbeat period, with respect to both time variables t and t′,
expressed as
hlinkl (t + T, t
′ + T ) = hlinkl (t, t
′) (56)
hnoden (t + T, t
′ + T ) = hnoden (t, t
′) ∀t, t′∈R .









hmodelk (t, t − τ)e
− jkω0tdt , (57)
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where model and m correspond either to link and l, or to node and n, respectively, ω0 is the
angular heartbeat frequency, and τ is an auxiliary time variable. According to the Fourier
series theory [51], we can express the relation between the drug delivery rate ym(t) at the







hmodel,mk (τ)xm(t − τ)dτ. (58)
If we define Ym(s), Hmodel,mk (s), and Xm(s) as the respective Laplace transforms of ym(t),




Hmodel,mk (s − jkω0)Xm(s − jkω0). (59)
The expression in (59) can be transformed into a matrix multiplication by defining the



















where [·]′ denotes the matrix transpose operation. As a consequence, the expression (59) is
transformed into a linear matrix relationship:
Ym(s) = H
model
m (s)Xm(s) . (63)
Hmodelm (s) is the Harmonic Transfer Matrix (HTM) of the arterial link l, in case model = link
and m = l, or the bifurcation node n, in the case where model = node and m = n. In
practice, the infinite matrices Hmodelm (s) and the vectors Ym(s) and Xm(s), are truncated to
contain only the significant harmonics [54].
Using the HTM for every link and node, it becomes possible to obtain the HTM HI,O(s)
of the drug propagation network model between the location of injection I and the tar-
geted site O, which allows to compute the LPTV impulse response hI,O(t, t′) through the
expressions in (55) and (54). This is accomplished using the two following rules:
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• The cascade rule, which states that the harmonic transfer matrix H◦m,m′(s) of the
cascade of two network models m and m′, which can be links, nodes, or combi-
nation thereof, is obtained by multiplying their respective harmonic transfer matrices
Hmodelm (s) and Hmodel
′





m′ (s) . (64)
• The parallel rule, which states that the harmonic transfer matrix H‖m,m′(s) of the par-
allel of two network models m and m′, which can be links, nodes, or combination
thereof, is obtained by summing their respective harmonic transfer matrices Hmodelm (s)
and Hmodel′m′ (s) as follows:
H‖m,m′(s) = H
model
m (s) + H
model′
m′ (s) . (65)
By using the cascade rule (64) and the parallel rule (65), the HTM HI,O(s) of the drug








n (s) , (66)
where P(I,O) is the set of parallel paths p linking the location of injection I to the targeted
site O. Every path p ∈ P(I,O) is a sequence of link l and node n couples (l, n) (p =
{..., (l, n), ...}). Finally, the LPTV impulse response hI,O(t, t′) is computed by applying (66)
to the expressions in (55) and (54).
3.6 Numerical results
3.6.1 Topology
As a numerical application of our model, we choose to study drug propagation between one
location of injection I and four different targeted sites O2, O4, O8, and O17. These locations
are different points in the small artery tree taking root at the renal artery as represented in



























Figure 18. Tree of small arteries at the end of the renal artery with their corresponding link numbers.
arteries dimensions presented in Table 1 and their topology represented in Fig. 21 collected
from anatomical data [37].
In Fig. 18, the geometry of the renal arterial tree is illustrated. The topology reflect-
ing the asymmetry of small arteries geometry and their reducing lengths are explained in
3.4.2. The numbers in the figures correspond to the link indexes l. The arteries with ra-
dius rl inferior to rmin = 0.8mm are not included, in fact, when the artery radius is smaller
than rmin = 0.8mm, the subtree is truncated, and replaced with a leaf with null hydraulic
impedance as explained in Sec. 3.4.2.1. where γ is called the asymmetry ratio and ξ is a
parameter that characterizes the turbulence of the flow. Physiological studies yield values
γ = 0.41 of the asymmetry ratio and ξ = 2.76, which characterizes the turbulence of the
flow. Using these values, we get asymmetry factors α = 0.9 and β = 0.6.
3.6.2 Cardiovascular Network Model
The blood velocity network model was validated against the magnetic resonance measure-
ments made available by [55], which was used to validate a model implemented numeri-
cally by finite difference methods. Fig. 19 compares the flow rate measurements in three
locations of the cardiovascular system, namely, the descending aorta, the iliac, and the
femoral arteries, with the flow rates obtained using the transmission line model developed
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in Sec. 3.4. We see a very good agreement between the experimental measurements and
the results of the developed model. We used the same topology as in [55], and we used the
flow measured in the aortic arc as an input to the cardiovascular network model.
3.6.3 Drug Propagation Network
The LPTV impulse response h(t, t′) is calculated for a fixed location of injection I set at
the inlet of the arterial tree, and different targeted sites O2, O4, O8, and O17, located respec-
tively at the outlet of links 2, 4, 8, and 17. A change of variables is performed on h(t, t′)
for a better representation, such that h
′
(t, τ) = h(t, t − τ). t is the periodic time variable, in
which the LPTV impulse response is T-periodic:h
′
(t, τ) = h
′
(t + T, τ). τ is the propagation
time variable: h(t, τ) → 0 as τ → +∞. A 3D representation of the functions h
′
(t, τ) is
rendered in Fig. 20. In Fig. 20a, we can observe the LPTV impulse response goes to zero
after a propagation period of 1200ms. It can be seen that the time-variance is significant.
In fact, we obtain two main peaks in the impulse response for the link 2 in Fig. 20 b),
separated by an important fading, due to the considerable blood velocity fluctuations in
that artery. In Fig. 20e, the drug propagates through link 2 with LPTV impulse response
hlink2 (t, τ), with radius r2 = 2.5mm, and a link 2 with LPTV impulse response h
link
4 (t, τ), with
radius r4 = 2.2mm, passing by a node 2 with LPTV impulse response hnode2 (t, τ). Due to
the bifurcation, the cascading of these two links and node causes a spread of the delay and
slower convergences to zero of the equivalent LPTV impulse response between I and O4.
In Fig. 20g, the drug propagates through an additional node 4 with LPTV impulse response
hnode2 (t, τ), and an additional link 8 with LPTV impulse response h
link
8 (t, τ). The bifurcation
effect is slightly more pronounced here, with a considerable portion of the drug rate that
is lost at the node. The drug delivery rate experiences a drop after the the peak and then
converges slowly to zero which would cause a dispersion of the drug between I and O8.
In the preceding examples, we chose a path through the left links which, by geometrical
asymmetry, experience a higher blood velocity compared with the right links. In Fig. 20e,
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Figure 19. Comparison of the flow rates calculated using the transmission line model with physiological
measurements in various locations of the cardiovascular system.
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Figure 21. Topology of large arteries.
we consider that the drug network includes an additional node 8 with LPTV impulse re-
sponse hnode8 (t, τ), and an additional link 17 with LPTV impulse response h
link
17 (t, τ) which is
positioned to the right. Since the node 8 relays most of the drug rate to the left link which
has much higher effective diffusivity, a more significant portion is lost to the left link. The
asymmetry of the small arteries tree causes most of the drug to be propagated in the left-
most blood links in the tree of small arteries. Here, the dispersion is more pronounced, and
the reflections from the preceding nodes is apparent.
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Table 1. List of large arteries and their dimensions





1 Ascending aorta 1 1.525 1.502
3 Ascending aorta 3 1.502 1.42
4 Aortic arch 3 1.42 1.342
12 Aortic arch 4 1.342 1.246
14 Thoracic aorta 5.5 1.246 1.124
15 Thoracic aorta 10.5 1.124 0.924
27 Abdominal aorta 5.25 0.924 0.838
29 Abdominal aorta 1.5 0.838 0.814
31 Abdominal aorta 1.5 0.814 0.792
33 Abdominal aorta 12.5 0.792 0.627
35 Abdominal aorta 8 0.627 0.55
36 External iliac 5.75 0.4 0.37
37 Femoral 14.5 0.37 0.314
40 Femoral 44.25 0.314 0.2
38 Internal iliac 4.5 0.2 0.2
39 Deep femoral 11.25 0.2 0.2
2 Coronaries 10 0.35 0.3
5 Brachiocephalic 3.5 0.95 0.7
6,17 Subclavians 3.5 0.425 0.407
9,19 Brachials 39.75 0.407 0.25
10,21 Radials 22 0.175 0.175
11,20 Ulnars 22.25 0.175 0.175
8,18 Vertebrals 13.5 0.2 0.2
7 R. carotid 16.75 0.525 0.4
13 L. carotid 19.25 0.525 0.4
16 Intercostals 7.25 0.63 0.5
28 Sup. mesenteric 5 0.4 0.35
22 Celiac 2 0.35 0.3
23 Hepatic 2 0.3 0.25
24 Hepatic 6.5 0.275 0.25
25 Gastric 5.75 0.175 0.15
26 Splenic 5.5 0.2 0.2
30,32 Renals 3 0.275 0.275
34 Mesenteric 3.75 0.2 0.175
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3.7 Conclusions
The goal of a Drug Delivery System (DDS) is to provide a localized drug presence where
the medication is needed, while, at the same time, preventing the drug from affecting other
healthy parts of the body. Amongst others, the most advanced solutions use drugs com-
posed of micro or nano-sized particles (particulate DDS) that are able to cross barriers
to the transit of particles out of the bloodstream. The Molecular Communication (MC)
paradigm abstracts the propagation of information between a sender and a receiver realized
through mass transport phenomena, since information-bearing molecules have to physi-
cally cover the distance from one location to the other. In this chapter, we advocate for the
Molecular Communication (MC) paradigm as a straightforward and efficient abstraction of
a particulate DDS, thus enabling the control and prediction of particulate drug delivery by
using tools from communication engineering.
In this chapter, we realized the molecular communication abstraction of a particulate
DDS by developing a MC channel model of the drug particle propagation through the car-
diovascular system. For this, we identified two separate contributions within the model,
namely, the cardiovascular network model and the drug propagation network model. The
cardiovascular network model allows to analytically compute the blood velocity profile
in every location of the cardiovascular system from the knowledge of the blood pressure
profile and flow input from the heart. The drug propagation network model allows the an-
alytical expression of the drug delivery rate at the targeted site from the knowledge of the
drug location of injection and injection rate profile. The derived model takes into account
also the individual specificities in the physiological parameters of the cardiovascular sys-
tem, such as the compliance of the blood vessels, heartbeat rate profile and the heartbeat
stroke volume. An example application of the developed model is also presented through
numerical results to assess the flexibility and accuracy of the analytical results of this work.
We propose as future work to investigate the safety issues of MC for the human being.
First, care should be taken to ensure that the drug concentration does not reach toxic levels
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in the body. Second, the interaction with naturally-occurring MC phenomena in the body
such as the cell signaling through the endocrine system should be considered. Third, the
MC system should be resilient against possible ‘malicious’ attacks. Such attacks may be
undertaken by benign bacterial and viral organisms, which develop defenses against the
therapy, or by the immune system which considers the foreign therapeutic agent as an
intruder to the body. Safety issues of MC could be studied in analogy with security issues
in classical communication systems.
The results detailed in this chapter open up the possibility to study optimization tech-
niques for particulate DDSs which could allow a careful selection of the location of injec-
tion and drug injection profile with the goal of obtaining a desired drug delivery profile at a
targeted site while minimizing the drug presence in the rest of the cardiovascular system. In
addition, the models developed in this research could potentially serve to investigate novel
communication techniques for Intra-Body Communication (IBC) networks.
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CHAPTER 4
MOLECULAR COMMUNICATION NOISE AND CAPACITY
ANALYSIS FOR PARTICULATE DRUG DELIVERY SYSTEMS
4.1 Motivation and Related Work
Particulate Drug Delivery Systems (PDDS) are therapeutic methods that use drug nanopar-
ticles to specifically target the cause of the disease while avoiding to affect other healthy
parts of the body. Drug nanoparticles are able to penetrate inside the body cells to de-
liver therapy, and therefore can bypass all physiological barriers that are in place inside the
human body to protect it from foreign elements. The PDDS aims to engineer drug nanopar-
ticles not only in terms of their chemical properties, size, and shape, but also in terms of the
injection pattern, location, and other mechanisms that enable the optimal reception of drug
nanoparticles by the diseased cells. By analyzing the PDDS, it is possible to know exactly
where the drug accumulates in the body, measure the efficiency of the PDDS solution, and
optimize the drug injection pattern.
The modeling of complex spatiotemporal dynamics of drug nanoparticles has been
identified as one of the major challenges to develop a new generation of efficient thera-
pies [56]. From the drug injection site, to the absorption by diseased cells, the nanoparticles
undergo several biophysical processes that are noisy in nature. In this chapter, an analytical
noise model of the PDDS in the human body is derived, reflecting all the possible noise
effects for the PDDS. First, the drug injection may suffer from imprecision due to the in-
jection device limitations, the pressure difference between the syringe and the blood flow,
and the creation of turbulences around the needle. Second, the nanoparticles are randomly
dispersed by the possibly turbulent blood flow in an intricate network of irregularly shaped
blood vessels, and exhibiting Brownian motion. Third, the penetration of drug nanopar-
ticles to the tissues surrounding the blood vessels is complicated by the stochastic nature
of the chemical reactions, and the time-varying mechanical forces interfering with these
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chemical reactions.
Our previous work in [57] uses transmission line theory to obtain the blood veloc-
ity everywhere in the cardiovascular system, and uses the theory of Taylor dispersion
to obtain the deterministic drug propagation in the body from the injection to the deliv-
ery point. In this chapter, the Fokker-Planck equation and the theory of inhomogeneous
Poisson processes are used to mathematically derive a new stochastic and information-
theoretical framework to model the random transport and binding of nanoparticles in the
cardiovascular system and to quantify the effect of noise through the use of the concept of
the information-theoretical capacity. This analysis uses the expressions obtained in [57]
to estimate several parameters, namely the blood velocities and the PDDS drug propaga-
tion probability. The noise and capacity analysis fills an important limitation in [57] in
regards to the random behavior of drug nanoparticles. An end-to-end Molecular Commu-
nication (MC) framework is proposed to analyze the noise effects in the PDDS. The novel
MC paradigm [2], where the information is conveyed through molecules, instead of the
conventional electromagnetic signals, is employed to enable the communication in biolog-
ical environments that are governed by molecular signals, such as bacterial communica-
tion [58] [16], with the long-term aim of establishing communication networks between
nanomachines inspired by intracellular signaling.
In the literature, the noise effects in the intercellular communication are shown to have
both beneficial and detrimental effects in intracellular MC [59]. The noise in MC by diffu-
sion is analyzed in relation to the underlying physical processes [11]. Also, the stochastic
effects in the ligand-receptor binding kinetics and interference are modeled through the MC
framework [12] [60]. The maximum achievable information rates in diffusion-based MC
under the constraints of Brownian motion noise are derived in [13] by using a novel ther-
modynamic information theoretical framework. These existing models rigorously reflect
the unique noise effects in MC, but they cannot be directly applied for the PDDS in the
complex cardiovascular network [57], because they assume linear time-invariant channel
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models for the propagation medium, which is not realistic to assume in the cardiovascular
system where the blood flow is highly time-varying, and they suppose diffusion in the free
and isotropic space (i.e. the molecules propagate in all the Cartesian directions in the same
manner and without any obstacles), while the MC in the cardiovascular system is confined
to the complex topology of blood vessels. The MC reception of nanoparticles is also heav-
ily affected by the blood flow that interferes with the chemical interactions between ligands
and receptors [17].
In addition to the analysis of the noise effects in the PDDS, the use of information the-
ory is proposed to evaluate the performance of the PDDS through the MC paradigm. The
main objective of the PDDS is to engineer a system that can induce a therapeutic effect in
the location where it is needed. The desired drug delivery at the location of the disease may
vary from one individual to another, depending on the nature and the stage of the illness,
the genomics that greatly affect the binding of drug nanoparticles to the receptors in the dis-
eased cells [61], and the desired intensity of the treatment. Therefore, it is highly desirable
that, for a given clinical setting, the PDDS can be employed effectively and reliably for the
treatment of a diversity of individuals. In this chapter, the PDDS is considered to be similar
to a communication system, where the drug injection which corresponds to a signal trans-
mission, induces the drug reception which corresponds to a signal reception, after being
distorted by the human body which corresponds to the communication channel. Through
this paradigm, the set of desired responses may be viewed as an alphabet of different re-
sponses yA, yB, . . . , yZ, etc. If the PDDS can reliably deliver different kinds of responses
unambiguously at the same time, this PDDS can be qualified to be very performant. The
size of this alphabet can be measured in bits (1 bit for two possible different therapeu-
tic responses, 2 bits for four possible different therapeutic responses, etc.). The existing
PDDS models are mostly based on deterministic approaches, while stochastic approaches
are mainly developed for the purpose of statistically estimating the required parameters of
the system from experimental results. In this chapter, based on the comprehensive model
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of the noise effects in PDDS, the capacity of the PDDS under the constraints of the noise
effects is mathematically derived, and this concept is used to evaluate the performance of
the PDDS. The expression of the capacity can be used as an objective function encompass-
ing all the PDDS parameters in order to optimize its design and the drug injection rate.
In classical communication theory, this optimization is solved through the water-filling al-
gorithm which assists in designing the transmitted signal in such a way that most of the
power is used in clear channel conditions, and the power is minimized in noisy channel
conditions. Similarly, in the PDDS, this analysis will enable to construct a drug injection
rate that transmits most of the valuable drug nanoparticles when the chances of having them
absorbed are high, and a minimal amount of drug nanoparticles when the chances of their
non-targeted dispersion is inevitable.
The paper is organized as follows: First, in Section 4.2, all the noise effects that exist
in the PDDS are presented, which are going to be modeled by using the MC paradigm.
Second, in Section 4.3, the elements of the MC abstraction of the PDDS noise effects are
presented, and the notion of capacity in the PDDS is defined and justified. Third, the
MC end-to-end drug reception noise is derived in Section 4.4. Fourth, in Section 4.5, the
MC capacity of the PDDS is derived within an information theoretical framework, and is
expressed as a function of all parameters of the noise effects from the drug injection to
the drug reception by diseased cells. Fifth, a kinetic Monte-Carlo scheme of the PDDS
in the cardiovascular system is described in Section 4.6, and the numerical results from
this scheme are compared with the analytical MC noise. Finally, Section 6.8 concludes the
paper by discussing the key outcomes of the MC noise modeling for the PDDS, the PDDS
capacity, and its application to the design and optimization of the PDDS.
4.2 PDDS Noise Scheme
The PDDS noise scheme consists of all the noise effects that affect the injection, propa-
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Figure 22. MC noise effects in particulate drug delivery systems.
effects are identified in the PDDS:
• The drug injection noise is caused by the mechanical limitations of the drug in-
jection device. The drug injection device is a computer-controlled infusion syringe
pump that allows the control of the drug injection rate in the drug injection site. This
device is likely to suffer from imperfections that cause an inaccurate drug injection
rate. Also, the drug injection device cannot be controlled arbitrarily fast, because
of the mechanical friction and compression phenomena occurring in the pump. In
addition, the drug injection rate is limited by the toxicity level. All these effects will
be considered for the MC noise and capacity modeling of the PDDS.
• The drug propagation noise is due to the stochastic nature of the motion of drug
nanoparticles in a possibly turbulent blood flow. After being injected, drug nanopar-
ticles are lost randomly at the level of blood vessel bifurcations, towards organs
and tissues where their effect is not desired. Especially at high concentration lev-
els, drug nanoparticles become more agitated, causing a noticeable Brownian noise
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effect, since drug nanoparticles try to move from the regions with high concentration
to the regions with low concentration.
• The drug reception noise affects the reception of drug nanoparticles by the diseased
cells. In fact, the ligand-binding interactions by which drug nanoparticles bind to the
surface of diseased cells is very stochastic. The diseased cells surface is a site where
different kinds of energies interact, such as the kinetic energy due to the blood flow,
the chemical energy of reaction between the ligands and the receptor, characterized
by a chemical potential, and the thermal energy related to the Brownian motion in
the blood medium. The small surface of interaction, irregularities in the cells, the
weakness of the chemical affinity between ligands and receptor, and the negative
effect of blood flow, which impede the drug delivery to the diseased cells.
These noise effects are numerous, complex, and inter-dependent, making their model-
ing tedious and challenging. However, the MC paradigm is well suited to address these
issues. In fact, it provides a comprehensive PDDS noise from the drug injection to the drug
reception, and enables the performance evaluation of the PDDS through the concept of the
capacity.
4.3 MC Noise And Capacity Abstraction for the PDDS
The MC Noise And Capacity Abstraction for the PDDS provides the model of the noise
effects in the PDDS, how the aggregate consequences of the noise effects are evaluated by
using the concept of the capacity, and how the noise is validated by using kinetic Monte-
Carlo simulations. As illustrated in Fig. 23, the PDDS is modeled as an MC channel with
the following components:
• The MC Transmitter represents the drug injection device, which applies a drug
injection rate x(t) at the drug injection site, where the drug injection device syringe
is inserted.
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Figure 23. Elements of the MC abstraction of the noise effects in the PDDS, and their relationship with
the PDDS capacity.
• The MC Channel reflects the effect of the blood flow on the propagation of drug
nanoparticles in a complex network of interconnected blood vessels. As presented in
our previous work [57], the PDDS channel is characterized by a time-varying drug
propagation probability h(t, τ), and by cross-sectional blood velocities in every blood
vessel l, denoted by {ul(t); l ∈ CV}.
• The MC Receiver is the set of the diseased cells that require the PDDS thera-
peutic effect. The MC receiver, located in the drug reception rate y(t), receives
drug nanoparticles through the ligand-binding mechanism. This mechanism allows
ligand-coated drug nanoparticles to have a high affinity to receptors located in the
surface of the diseased cells. The MC reception is complicated due to the fact that
the influence of the blood flow on the affinity between ligand and receptors varies
periodically with time.
MC noises for all the components of the PDDS system are provided. These noises are
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derived individually and then combined to obtain the aggregate effect of the end-to-end
drug reception noise in the PDDS, as follows:
• The drug injection noise describes the noise limitations of the drug injection device.
This model depends on the maximum injection rate A(t), the sampling period Ts, the
average drug injection constraint, and the drug leakage rate η(t). In Section 4.4.1,
these noise limitations are formulated depending on the pump injection syringe.
• The drug propagation noise depends on the drug diffusivity D and the topology of
the cardiovascular system. In Section 4.4.2, a detailed probabilistic derivation of the
drug propagation noise is provided, which gives the drug propagation probability
h(t, τ), where t and τ are time variables.
• The drug reception noise gives the probability that drug nanoparticles located in
the drug reception site are received by the diseased cells through the ligand-binding
mechanism. This model depends on the number of ligands in a drug nanoparticle
NL, the number of receptors in the diseased cells NR, the temperature Tp, the drug
nanoparticle spheroid dimensions, with a radius a and an aspect-ratio γ, the maxi-
mum attraction distance ξ, the bond equilibrium length ζ, the characteristic length
χ, and the cross-sectional average blood velocity at the drug reception site ul(t). In
Section 4.4.3, these parameters are explained in detail, and are related to the drug
reception probability pr(t).
These noise effects are aggregated to obtain an end-to-end model of the MC noise effects for
the PDDS. In this chapter, it is found that the drug reception rate y(t) is an inhomogeneous







where Pois (.) denotes the Poisson distribution.
58
Based on the result in (67), the MC capacity of the system is presented which is a
measure derived from information theory quantifying how much the drug injection rate
x(t) can reliably affect the drug reception rate y(t) under the constraints of the various









where αn,m is an expression of the drug propagation probability and the drug reception
probability at the drug injection time sample n and the drug reception time sample m, An is
the maximum non-toxic number of drug nanoparticles at the time nTs, pm is a coefficient
depending on the maximum drug reception rate and the drug reception noise, m is the
drug injection time sample, n is the drug reception time sample, M is the length of the
discretized MC channel memory, N is the length of the drug injection rate x(t), ψm (·) is a
function depending on the drug injection noise parameters, the drug leakage rate, and the
drug injection time sample m. The MC channel for the PDDS is unique in many senses.
First, it is not Gaussian, as it is often assumed to derive the capacity in molecular and
electromagnetic communications. Second, all its parameters are time-varying. Third, the
PDDS channel has important memory effects due to the spread by diffusion.
Regarding inter-individual variations, one of the main advantages of the MC approach
is that all system parameters are directly related to the physiology of the patient and the
chemical properties and shape of drug nanoparticles (cf. Fig. 23). This allows the design
of personalized medicine that is specific to each individual. The existing pharmacokinetic
models use statistical methods to estimate the parameters of the system, which are valid
only for one individual. The MC model allows the incorporation of individual variabilities
mathematically.
Finally, the PDDS end-to-end noise is validated by comparing the results with simula-
tion obtained by a kinetic Monte-Carlo scheme presented in Section 4.6.
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Figure 24. Elements of the drug injection noise.
4.4 Drug Delivery Noise
The drug reception noise allows to probabilistically describe the noise effects from the
drug injection to the drug reception. Here it is shown that the drug reception rate y(t) is an
inhomogeneous Poisson process related to the drug injection rate x(t) as expressed in (67).
4.4.1 Drug Injection Noise
The drug injection noise is composed of all limitations and noise effects that are caused by
the imperfections of the drug injection device, as illustrated in Fig. 24. Our PDDS scheme
requires that the drug injection rate is controllable. Here the drug injection rate is assumed
to be modulated by an infusion pump syringe, which is connected to a computer system.
The computer system is programmed to induce a desired drug injection rate by changing
the pressure of the infusion pump. The drug injection device creates the following limiting
factors:
• The injection leakage, which is the uncontrolled leaking of drug nanoparticles from
the tip of the needle. The pump infusion syringe can leak drug nanoparticles because
of the concentration gradient between the drug solution, and the pressure difference
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between the needle and the blood flow. The leakage is independent of the drug in-
jection rate x(t). Since the blood flow is periodic, the drug leakage ratevaries peri-
odically, and creates additional drug nanoparticles in the drug reception site. The the
drug reception rate is expressed as follows:
y(t) = g(x(t)) + η(t) , (69)
where g(x(t)) represents the part of the drug reception rate that is dependent on the
drug injection rate x(t). Since the drug propagation is linear, the drug delivery rate
η(t) depends on the drug syringe spill rate ι(t) as follows:
η(t) = g(ι(t)) . (70)
The leakage is supposed to be slower than the drug injection. Therefore, the drug
leakage rate η(t) is also sampling rate limited by the sampling period Ts.
• The maximum injection rate is limited, because the drug injection rate should not
create a drug concentration of drug nanoparticles that is toxic to the location where
the drug is injected. This constraint is expressed as follows:
x(t) ≤ A(t) , (71)
where A(t) is a periodic function (A(t) = A(t + T )), which specifies the maximum
drug injection rate during a heartbeat period, and T is the blood velocity period. The
maximum drug injection rate will vary with time due to the periodic blood flow.
• The sampling rate is the maximum rate at which the drug injection can be changed
in time. This rate is limited by the mechanical deficiencies of the pump infusion
syringe, such as the friction of the syringe rubber piston, or the presence of small
compressible gas bubbles in the solution. Therefore, the drug injection cannot be
arbitrarily fast. The maximum sampling rate limitations is expressed as follows:
| f | ≥
1
Ts
=⇒ X( f ) = 0 , (72)
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y(t) :  Drug reception rate
Rate λ '(t) = (1− pr (t))λp (t)
y '(t) :  Drug loss rate
Rate λ(t) = pr (t)λp (t)
Figure 25. Drug nanoparticle reception as the time-varying splitting of an inhomogeneous Poisson
process.
where f is the frequency and X( f ) is the frequency transform of the drug injection
rate x(t).
4.4.2 Drug Propagation Noise
The drug propagation noise gives a probabilistic description of the presence of drug par-
ticles in the delivery site. The drug propagation along the cardiovascular system is noisy
because of the Brownian motion of drug nanoparticles, which are randomly dispersed in
the blood vessels, and lost at vessel bifurcations to regions of the body where the drug is not
needed. Here it is shown that drug nanoparticles that propagate to reach the drug reception







where yp(t) is the drug propagation rate which denotes the number of drug nanoparticles
that reach the drug reception site at the time t as shown in Fig. 25.
4.4.2.1 Drug Propagation Poisson Binomial Noise
This gives the drug propagation rate yp(t) at the drug reception site, given a drug injection
rate x(t), as a function of the probability that one single drug nanoparticle injected at the
time τ in the drug injection site is located at the drug reception site at the time t, which is
denoted by ps(t, τ), which is the single drug nanoparticle propagation probability devel-
oped in Section 4.4.2.2. The drug propagation Poisson binomial model expresses the drug
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where k is the number of nanoparticles that reach the drug reception site after propagation
in the cardiovascular system, ps(t,mTs) is the probability that one single drug nanoparticle
injected at a time τ at the drug injection site is delivered at the time mTs at the drug reception





with N the number of time samples drug injection rate x(t), such as the drug injection rate




x(nTs)δ(t − nTs) . (76)
The aforementioned relationship is proved by considering the probability that k nanopar-
ticles among a batch of x(nTs) nanoparticles, all injected at the time nTs, reach the drug
reception site at the time t. The probability that exactly k nanoparticles among the ones
enveloped in the drug injection rate x(t) be delivered at the time t is the probability that
the total number of nanoparticles among the N different batches that are successfully de-
livered is equal to k. In other words, the number of successful nanoparticle receptions is a
sum of independent Binomial trials each with different probabilities of success. Therefore,
yp(t) follows a Poisson binomial distribution [63], where the number of trials is the total
number of nanoparticles enveloped by the drug injection rate x(t), and the success rates are
the probabilities of the drug delivery for each nanoparticle m, with m = 0, . . . ,N − 1, as
expressed by (74).
4.4.2.2 Single Drug Nanoparticle Propagation Noise
This provides a description of the random movement of one nanoparticle injected in the
cardiovascular system. The probability that one single drug nanoparticle is delivered at
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the drug reception site at the time t if it is injected at the time τ is denoted as ps(t, τ). A
single drug nanoparticle delivery is found to follow a Bernoulli distribution with probability
ps(t, τ) that is equal to h(t, τ). This is proved based on the analogy between the advection-
diffusion equation and the Fokker-Planck equation, which is the basis of the random motion
of drug nanoparticles. A deterministic model of the movement of drug nanoparticles in
the cardiovascular system is proposed in [57]. The deterministic model was based on the
generalized Taylor dispersion equation that governs the cross-sectional concentration of
drug nanoparticles c(z, t) under the effect of advection by a fluid with cross-average velocity










where ∂ is the symbol for the partial derivative. Since the advection-diffusion equation does
not capture the micro-scale variations in the propagation of nanoparticles, the deterministic
model that solves it is only adequate for describing the average space and time evolution
of the movement of drug nanoparticles. Therefore, a stochastic model is needed to reflect
both the macro-scale and micro-scale variations in the movement of drug nanoparticles.
The stochastic nature of drug nanoparticles is described by the Fokker-Planck equation
[64]. The Fokker-Planck equation is the basis of dynamic techniques for obtaining the
random path of a drug nanoparticle subject to Brownian motion [65]. The one-dimensional
form of the Fokker-Planck equation states that the position z(t) of the drug nanoparticles at










where µ(z, t) is the nanoparticle drift related to the advection process and D(z, t) is a func-
tion related to the diffusion process, such as, in the micro-scale, the position z(t) of the
nanoparticle is incremented by the random process dz(t) obeying the following stochastic
differential equation:
dz(t) = µ (z(t), t) dt +
√
2D (z(t), t)dw(t) , (79)
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where dw(t) is called a Wiener process, with the following probability density function:







The generalized Taylor dispersion equation (77) and the Fokker-Planck equation (78) have
the same form, and therefore, by assuming spatially uniform drift and diffusivity, and by
taking the drift term µ(z, t) to be equal to the cross-sectional average velocity u(t), the
equations become identical. Given that these equations are linear, it is possible to conclude
that the deterministic solution of the advection-diffusion equation c(z, t) and the probability
density function of the movement of a drug nanoparticle p(z, t) are equal to each other up




c(z, t) , (81)
where c0 is the multiplicative constant, which is obtained from the fact that the integral of






c(z, t)dzdt , (82)
where CV denotes the spatial domain in the cardiovascular system, z is the space coordi-
nate, and t is the time coordinate. From the results above, the probability density function
that describes the drug propagation rate yp(t) close to a drug reception site by interpret-
ing the time-varying impulse response h(t, τ) at a drug reception site for an input at drug
injection site can be expressed as a probability density function. The time-varying drug
propagation probability of the PDDS h(t, τ) is equal to the drug propagation rate c(z, t) at
the longitudinal coordinate z = `l with a drug injection rate x(t) equal to an impulse δ(t− τ)
centered around the time τ, as expressed in the following:
c(z, t)|x(t)=δ(t−τ),z=`l = p(z, t)|z=`l . (83)
It follows by definition that:
h(t, τ) = ps(t, τ) . (84)
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Figure 26. Ligand-binding reception scheme.
Therefore, the probability that k nanoparticles (k ∈ {0, 1}), injected at the time t − τ at the






= hk(t, τ)(1 − h(t, τ))1−k , (85)
where ys(t) denotes the number of drug nanoparticle located at the drug reception site.
4.4.2.3 Drug Propagation Poisson Noise
This provides an approximation of the drug propagation Poisson binomial noise described
in Section 4.4.2.1. By using Le Cam’s theorem [66], a Poisson binomial distribution can
be approximated by a Poisson process with a rate equal to the sum of the probabilities of
the Poisson binomial distribution. Therefore:
y(t) ∼ Pois (λ(t)) , (86)
where Pois(λ(t)) denotes an inhomogeneous Poisson process with rate λ(t). The rate λ(t)




x(τ)h(t, τ)dτ . (87)
4.4.3 Drug Reception Noise
The drug reception noise provides the probability that particles that reach the drug recep-
tion site after propagating in the cardiovascular system will be received by the diseased
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cells, which are here modeled as an MC receiver, through the adhesion to the cells and
absorption into the interior of the cell. This reception process is characterized by a drug
reception probability pr(t). The time-variance is due to the periodic blood flow, which
affects the ligand-binding mechanism by which drug nanoparticles are received by the dis-
eased cells.
The study of MC stochastic receiver models is proposed in [12] in a diffusion-based
environment, which allows simulating the random behavior of the chemical reactions of an
MC receiver. Such diffusion-only MC models would not accurately describe the ligand-
binding reception in a flow-dominated environment. In fact, several qualitative and experi-
mental studies [67] [17] have shown that flow creates a shear stress along the blood vessel
walls, which significantly affects the deposition and the reception of the drug nanoparticles.
The MC receiver proposed here is based on the mathematical modeling of receptor-
mediated endocytosis of nanoparticles under shear stress, which means the absorption of
drug nanoparticles inside blood vessel wall cells under the effect of the blood velocity [68].
As shown in Fig. 26, this model is extended by taking into account the blood velocity
ul(r, t) in the drug reception site, the size of the diseased region, and the parameters of the
drug nanoparticle coating. The MC receiver model scheme is pictured in Fig. 27. The MC
receiver is affected by the following elements and parameters:
• The nanoparticle characteristic size a, which is equal to the radius for a sphere.
• The nanoparticle aspect ratio γ, which is equal to the ratio between the polar diam-
eter and the equatorial diameter of a spheroid-shaped nanoparticle. It is equal to one
for a sphere.
• The number of ligands NL is the total number of ligands that cover the nanoparticle
surface. The ligands are supposed to be uniformly distributed on the surface of the
nanoparticle. The density of the ligands is assumed to be the same for all nanoparti-
cles.
67
NR : Number of receptors












































βw (t) : Blood wall shear stress
Figure 27. Elements of the Drug Reception Noise.
• The number of receptors NR is the total number of receptors that are available in
the drug reception site. It is supposed that there are more receptors than ligands (i.e.
NR >> NL).
• The ligand-receptor bond characteristic length χ, which is the distance between
the ligand and the receptor when they are bound together without any external force
affecting the bond, and which is approximately equal to 0.1 nm.
• The ligand-receptor bond equilibrium ζ, which is the distance between the ligand
and the receptor when they are bound together in equilibrium under the effect of
shear stress.
• The ligand-receptor maximum attraction length ξ, which is the maximum distance
between the ligand and the receptor at which the bonding is possible.
It is supposed that a drug nanoparticle is delivered when at least one stable bond is
established between the nanoparticle and the drug reception site. This work is based on
classical results from [69] and [70]. In this chapter, the relationship between the drug
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reception probability and the time-varying blood velocity is derived. The resulting drug
















• r0 is the radius of the section of the nanoparticle located at a ligand-receptor maxi-

























• kB is the Boltzmann constant, which is approximately equal to the following:
kB = 1.4806488 × 10−23m2kg s−2 K−1 . (92)
• Tp is the blood temperature, which is approximately equal to 310 K.
• Fs is a coefficient that is proportional to the drag force due to the blood flow, and is
equal to Fs = 6+
(
10.416 − 0.8280γ + 0.768γ2 + 0.54γ3
)
e−γ , with γ the nanoparticle
aspect ratio.
• Rs is a coefficient that is proportional to the rotational moment of force due to the
blood flow, and is equal to Rs = 8 +
(
−164 − 372γ − 280γ2 + 71.6γ3
)
e−γ with γ the
nanoparticle aspect ratio.
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• βw(t) is the wall shear stress, which is derived below. Supposing the approximation
of blood flow as a Newtonian fluid, by definition, the shear stress βw(t) at the wall
is expressed as τ = µβw(t), where µ is the blood dynamic viscosity, which is ap-








where rl is the radius of the blood vessel located in the drug reception site. Based on









where i is the imaginary unit number, ω is the radial frequency, and α(ω) is the





















which is expressed as a function of the Bessel function of the first kind, and, respec-
tively, of the zero and first order, J0 (·) and J1 (·) [42]. Ul(ω) is the Fourier transform






Biologically plausible numerical values are used for the parameters for the PDDS. For
the numerical evaluation, it is considered that the nanoparticle size to be a = 20 µm, the
maximum attraction length ξ = 10−8 m, the bond characteristic length ζ = 5 · 10−9 m,
the receptor density mR = 5 · 1013 m−2, the ligand density mL = 3 · 10−3 m−2, the blood
density ρ = 1.06 ·103 kg ·m−3, the blood kinematic viscosity ν = 4.603 ·10−6 m2 · s−1, and
a spherical nanoparticle shape with γ = 1. The dimensions and topology of the considered
portion of the arterial network are presented in Fig. 30. The blood velocity network is cal-

























Figure 28. Drug reception probability in the drug reception site as a function of time.
to extrapolate for individuals of different ages by using empirical laws such as the Preece-
Baines model, which conforms to the human growth curve [72]. Fig. 28 shows how the
drug reception probability changes with respect to time during one heartbeat period. The
numerical evaluations show that properly designing the time pattern of the drug reception
rate y(t) can highly affect the efficiency of the PDDS.
4.4.4 End-to-End Drug Reception Noise
The end-to-end drug reception noise provides a model of the noise effects from the in-
jection to the reception of drug nanoparticles by the diseased cells. This model is based
on the drug injection noise (Section 4.4.1), the drug propagation noise (Section 4.4.2), and
the drug reception noise (Section 4.4.3). The following relationship between the drug re-
ception y(t), and the drug injection rate x(t), is obtained through this model as expressed
in (67). To prove the expression in (67), the property of splitting inhomogeneous Poisson
processes [73] is used. In fact, based on the Poisson approximation of the drug propagation
model presented in Section 4.4.2.3, the drug propagation rate yp(t) is an inhomogeneous
Poisson process with rate λp(t) expressed as follows:
λp(t) = η(t) +
+∞∫
−∞
h(t, τ)x(τ)dτ . (97)
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The delivered drug nanoparticles are received by the diseased cells according to the drug
reception probability pr(t) presented in Section 4.4.3. By using a property of the splitting
inhomogeneous Poisson processes [73] illustrated in Fig. 25, the drug reception rate is also
an inhomogeneous Poisson process with rate λ(t) expressed as follows:
λ(t) = pr(t)λp(t) . (98)
4.5 Capacity Analysis of the PDDS
Here the capacity of the PDDS expressed in (68) is derived based on the drug delivery noise





I(xN; yN) , (99)
where lim is the limit symbol, the drug injection sequence xN represents the drug injection
rate, and is defined by xN = [x1, . . . , xn, . . . , xN−1], where the n-th drug injection sample
xn is the number of drug nanoparticles injected at the time nTs and N is the length of the
drug injection sequence xN , the drug reception sequence yN represents the drug reception
rate, and is defined by yN =
[
y1, . . . , ym, . . . , yN+L−2
]
where the m-th drug reception sample
ym is the number of drug nanoparticles delivered during the time interval [mTs, (m + 1) Ts[,
and L is the channel memory. M = N + L − 1 is the length of the drug reception sequence.
The channel memory is defined as the number of time samples for which any drug injected
at the time τ is no longer observed at any time t larger than τ + LTs. The memory is here
considered finite, such as ∀ t, τ ∈ R t ≤ τ + LTs =⇒ h(t, τ) = 0, and I(xN; yN) is the
mutual information between the random drug injection sequence xN and the random drug
reception sequence yN .
4.5.1 Drug Injection Sequence
The drug injection sequence consists of N time samples of the drug injection rate, such as
it is possible to write the drug injection sequence as xN = [x(nTs) | n = 0, . . . ,N − 1]. By
using the Dirac function, the drug injection rate x(t) can be expressed as a function of the
72




xnδ(t − nTs) , (100)
where N is the length of the drug injection sequence xN . The drug injection rate is com-
posed of N Dirac functions, each delayed by n time samples, and weighted by the number
of injected nanoparticles at the time nTs. The drug injection sequence xN is subjected to
the two following constraints:
• the toxicity constraint, which limits the number of injected nanoparticle to a max-
imum allowed toxicity level. Beyond the toxicity level, the drug injection has an
adverse effect on the body. This constraint is written as follows:
∀n ∈ {0, . . . ,N − 1} xn ≤ An . (101)





xn = σ . (102)
4.5.2 Drug Reception Sequence
The drug reception sequence is a sequence of M random variables
[
ym | m = 0, . . . ,M − 1
]
,
which represent the number of delivered nanoparticles during each the Ts-long m-th time
duration. It is shown here that the number of nanoparticles delivered during the time inter-
val [mTs, (m + 1) Ts[ ym, which is called the m-th drug reception sample, follows a Poisson
distribution with rate λm expressed as ym ∼ Pois(λm), where the rate λm is expressed as:




with ηm the discrete drug leakage rate in the drug reception site at the m-th time sample (i.e.




h(t, t − nTs)pr(t)dt . (104)
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where h(t, t − nTs) denotes the time-varying drug propagation probability with injection
time t − nTs and observation time t. In the following part of this section, the derivation
of the result in (103) is presented. The result is obtained in (103) by moving from the
continuous domain of Poisson processes to the discrete domain of Poisson distribution.
This is performed by building the Poisson distribution ym from the Poisson process y(t) as
the expected number of drug nanoparticle deliveries in the interval [mTs, (m + 1) Ts[. The
rate of ym is the integrated continuous rate of the inhomogeneous Poisson process y(t) in













x(t − τ)pr(t)h(t, τ)dτ
)
dt , (105)








pr(t)h(t, t − nTs)dt
 . (106)
Finally, by using the definition of the coefficients αn,m in (104), the following expression of
the rate λm is obtained:





The mutual information between the drug injection sequence xN and the drug reception
sequence yN used in (99) is as follows [75]:
I(xN; yN) = H(yN) − H(yN | xN) , (108)
where H(yN | xN) is the conditional entropy of the drug reception sequence defined as:








where pyN | xN is the conditional probability mass function of the discrete random variables
y1, y2, . . . , yM−1 of the drug reception sequence given the occurence of the discrete ran-









where pyN is the joint conditional probability mass function of the discrete random variables
y1, y2, . . . , yM−1 of the drug reception sequence. In the following, the derivation of the
conditional and marginal entropies of the drug reception sequence is presented.
4.5.2.2 Conditional Entropy
The conditional entropy is expressed in (109). Conditioned on the drug injection sequence,
the drug reception samples {ym; m = 0, . . . ,M − 1} are independent and have the probability
mass function pym | xN . It is then possible to write:
H(yN | xN) =
M−1∑
m=0
H(ym | xN) , (111)
where H(ym | xN) is the conditional entropy of the m-th drug reception sample given the
occurrence of the drug injection sequence xN . H(ym | xN) is by definition equal to the fol-
lowing [75]:







where E [·] is the expectation operator, pym | xN denotes the conditional probability mass func-
tion of the m-th drug reception sample given the occurrence of the drug injection sequence
xN . By identification with the Lemma 1 obtained in [76],the conditional entropy H(yN | xN)
can be expressed as follows:










E [λmTs] . (113)
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4.5.2.3 Marginal Entropy
The marginal entropy in (110) of the drug reception sequence is derived. The drug recep-
tion samples {ym; m = 0, . . . ,M − 1} are independent and have the probability mass func-
tion pym | xN . Therefore, the marginal entropy is H (yN) =
∑M−1
m=0 H(ym) , where H(ym) is the
marginal entropy of the m-th drug reception sample. H(ym | xN) is by definition equal to






where pym is the probability mass function of the m-th drug recep-
tion sequence.
By identification with the expression of the least-square estimator of Poisson-distributed
random variables performed in [76] by using semimartingale methods, and supposing that
the channel does not vary in time during Ts, the marginal entropy of the drug reception
sequence H (yN | xN) can be expressed as follows:












E [λmTs] , (114)
where λ̂m is the least-squares estimator of λm given the occurrence of the drug reception




. The least-squares estimator λ̂m of the rates λm can be





x̂nαn,m + ηmTs , (115)







The expression of the mutual information I(xN; yN) is obtained by substituting in (108)
the drug injection sequence conditional and marginal entropies by their expressions (113)
and (114), respectively, as follows:















where λ̂m is the least-squares estimator of the rate λm given the drug reception sequence yN .
By using the notation proposed in [77] for the treatment of the single-input single-
output Poisson channel, the mutual information in (117) can be rewritten as the difference
between two quantities, where the first is larger than the second, as follows:




























(ηm + Bm) log (ηm + Bm) − ηm log ηm
]
− (ηm + x) log (ηm + x) − ηm log ηm , (119)
where x is a variable of ηm, and Bm =
∑N−1
n=0 Anαn,m is the m-th drug reception sample
given the occurrence of a drug injection sequence at the maximum levels An (101) that
constrain it, and αn,m are the channel coefficients defined in (104). By identification with
the derivation in [77], the capacity is found to be closely bounded by the expression in (68)






, where sm is the ratio
between the reception noise and the average received number of drugs in the m-th sample,
which can be written as sm =
ηm
Bm







4.5.3 Spatial Capacity Numerical results
4.5.3.1 Effect of Blood Vessel Dimensions
Fig. 29(a)shows how the length of the blood vessel affects the performance of the PDDS
capacity. The longer the vessel is, the more dispersive the channel becomes, and therefore



























































































































(d) Effect of the diffusion coefficient on the capacity.
Figure 29. The effect of the drug parameters, the vessel dimensions, and the toxic level on the capacity
of the PDDS channel.
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blood vessel affects the performance of the system capacity. When the length of the vessels
is long, the variance of the drug propagation probability increases, which creates a more
severe memory effect, and reduces the capacity of the channel. Similarly, when the radius
of the vessels increase, the mixing along the radial coordinate is reduced, which makes the
drug propagation probability more dispersive.
4.5.3.2 Effect of Blood Velocity
Fig. 29(b) shows how the length of the blood vessel affects the performance of the system
capacity. At this regime, when the blood velocity becomes high, the channel becomes more
dispersive, and therefore the capacity of the channel is affected. However, due to the Taylor
dispersion effect, the blood velocity can actually reduce the dispersion in the channel, and
produce the opposite observationin some conditions.
4.5.3.3 Effect of Diffusion Coefficient
Fig. 29(a), shows how the diffusion coefficient affects the performance of the system ca-
pacity. The higher the diffusion coefficient is, the more dispersive the channel becomes,
and therefore the capacity of the channel is affected. When the diffusion coefficient is high,
the drug disperses faster in the blood, causing a longer delay and higher memory effect.
4.6 Monte-Carlo Simulation of the PDDS
In this section, a simulation method to study the propagation of a drug nanoparticle in
the cardiovascular system with unsteady flow by introducing a Monte-Carlo simulation
method of the PDDS is presented. The deterministic impulse response model developed
in [57] has been validated by using finite-element simulation on COMSOL in [78]. For the
noise analysis of the PDDS, the kinetic Monte-Carlo technique [49] is used to observe the
random path of nanoparticles caused by random Brownian motion and validate it against
the developed stochastic model. The random Brownian motion is generated by the model
described in Section 4.4. In the kinetic Monte-Carlo technique, the path of nanoparticles
is simulated by assuming that every nanoparticle is a random walker affected by Brownian
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motion (diffusion) and by a randomly fluctuating velocity field (convection).A model is
proposed where parameters of the Brownian are directly related to the diffusion coefficient
of the nanoparticles, and the random velocity field is generated by assuming that the radial
and transversal components of the blood velocity field are correlated Gaussian random
variables. The objective of the simulation is to study the effect of the blood turbulence on
the movement of drug nanoparticles, and to compare these results with the analytical model
of drug propagation.
4.6.1 Monte-Carlo Nanoparticle Random Walk
The stochastic differential equation governing the displacements of the nanoparticles ac-
cording to the Langevin equations [79] describing the movement of a drug nanoparticle in
a fluid are dz(t) = Re {uz(z, r, t)} dt + Gz
√
2Ddt and dr(t) = Im {ur(z, r, t)} dt + Gr
√
2Ddt,
where D is the nanoparticle diffusion coefficient defined, uz(z, r, t) and ur(z, r, t) are the ax-
ial and the radial components of the random blood velocity process at time t in the point
with coordinates (z, r) respectively, Re {·} is the operator giving the real part, Im {·} is the
operator giving the imaginary part, Gz and Gr are independent standard normal random
variables.
4.6.2 Monte-Carlo Simulation Results
Fig. 30(a)- 30(c) compare the drug propagation probability obtained by using the analyt-
ical for the PDDS and the drug propagation probability obtained by kinetic Monte-Carlo
simulation. The results are obtained by placing nanoparticles in the injection point of the
blood vessel network, and the nanoparticles that arrive to the drug delivery site of the blood
vessel network are counted as the simulation time advances. Fig. 30(a)-Fig. 30(c) show the
topologies of the corresponding networks. A good agreement between the analytical model
and the kinetic Monte-Carlo results is observed. The drug propagation probability obtained
by kinetic Monte-Carlo simulation is noisy because of the discrete number of nanoparticles









































































Figure 30. Comparison between the drug propagation probabilities obtained by the MC model and the
drug propagation probabilities obtained by the Monte-Carlo simulation for different delivery locations.
4.7 Conclusions
Particulate drug delivery systems (PDDS) aim to delivery a drug load to the parts of the
body where it is needed, at the right time and the right concentration levels, through the
use of drug nanoparticles that are able to penetrate inside the cells and unleash their drug
load. The analysis of the PDDS is crucial for the development of optimal drug delivery
formulations and techniques. The modeling of PDDSs allows the prediction of the locations
where drug nanoparticles propagate, their number, and the noisiness in their movement. It
has been shown in this chapter that the MC communication paradigm where the information
is conveyed through molecules enables a thorough analysis of the PDDS in the human
body. In fact, an MC model of the PDDS is developed, taking into account all the possible
physiological parameters of the system, such as the drug injection device, the propagation
in the intricate network of blood vessels, the time-variance and turbulence of the blood flow,
as well as the absorption of drug nanoparticles by the diseases cells through the ligand-
binding mechanisms.
Drug nanoparticles undergo many noise effects such as the injection noise, the blood
velocity turbulence, the ligand-binding noise, and the Brownian motion of nanoparticles.
In this chapter, these noise effects have been modeled through the MC paradigm where
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information is conveyed through the propagation of nanoparticles. These noise effects have
been modeled as interference in an MC system. The use of information theory was advo-
cated for the design of the PDDS. The analogy between the number of possible therapeutic
responses deliverable by the PDDS and the size of the alphabet in a communication system
was used. The PDDS was assessed as an efficient system if it is able to reliably deliver a
diverse set of therapeutic responses, depending on the stage and nature of the disease and
the individual specificities.
To our knowledge, this is the first work to propose the use of information theory in
the PDDS design. Other works were mainly based on deterministic and probabilistic anal-
ysis of the long-term drug distribution throughout the body. Our information-theoretical
approach can be applied to put into use high precision nanomedicine delivery, in contrast
with traditional medicine where the drug injection is not optimized with respect to the body
variabilities such as the blood flow, the ligand-binding kinetics, and their interaction.
The noise effects in the propagation of drug nanoparticles in the cardiovascular system
have been simulated by using kinetic Monte-Carlo simulations. The simulations show
a good agreement between the analytical model and the kinetic Monte-Carlo simulation
results. This study confirms that the MC paradigm can be conveniently used for the analysis
and optimization of the PDDS.
We suggest as future work to experimentally measure the distribution of drug nanopar-
ticles in the cardiovascular system at an accurate time and space scale. These experimental
results would be beneficial to validate the MC model. The existing experimental work on
the distribution of nanoparticles is constrained to study their space and time evolution on a
very large scale, in the order of hours and on the level of organs as a whole. We believe that
the advent of nanomedicine allows to control the drug injection at a much more accurate
resolution, and that therefore the distribution of nanoparticles should be studied in the order
of millimeters and seconds to develop a highly targeted PDDS.
The PDDS model makes it possible to engineer therapeutic solutions that are inspired
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by the naturally-occurring defense mechanisms that the body deploys to combat diseases
and anomalies in its functioning. The noise modeling is particularly important to the field
of cancer therapy, where the choice of low concentration of drug nanoparticles is made to
avoid toxic effect of the drugs, at the expense of the accuracy of the drug delivery. The
PDDS model provides quantitative models to find trade-offs between toxicity and drug
efficiency to facilitate cancer therapy. Ultimately, the MC paradigm can be used to create
bio-inspired molecular nanonetworks for the advanced nano-scale monitoring and healing
of the human body.
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CHAPTER 5
PHARMACOKINETIC MODELING USING MOLECULAR
COMMUNICATION
5.1 Motivation and Related Work
Targeted Drug Delivery Systems (TDDSs) [80] are cutting-edge therapeutic methods, which
aim at delivering the drug exactly where it is needed while minimizing the adverse effects
of the drug on the other healthy parts of the body, by using micro- or nano-sized drug-
loaded particles. The estimation of how the drug-loaded particles distribute within the
body, named biodistribution, is essential for TDDS engineering, and it is directly related to
the processes involved in the particle propagation, such as their advection and diffusion in
the blood stream, their absorption from surrounding tissues, and their chemical and physi-
cal interactions with other biomolecules present in the body. Although drug biodistribution
can be estimated empirically through clinical experiments, these are rarely performed be-
cause of the ethical and financial constraints they pose [81] and their specificity to each
individual subject.
Recent advances in biomaterials allow the engineering of drug particles with very spe-
cific chemical and geometric properties in order to provide a targeted drug delivery. To
benefit from these technological advances and study the properties of drug particles to
guarantee an optimal biodistribution, the aforementioned particle propagation processes
have to be modeled through the study of the so-called drug pharmacokinetics. The most
successful existing TDDS pharmacokinetic models are based on the multi-compartmental
approach [82], where large portions of the human body are considered as single compart-
ments, with homogeneous chemical and physical properties. The pharmacokinetics in one
compartment is commonly described through first-order differential equations, and the evo-
lution of the pharmacokinetics is obtained for a time scale in the order of hours. These
models include: i) TMDD (Target-Mediated Drug Disposition) [20], where the equations
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are based on a very limited number of parameters that are empirically derived; ii) PK/PD
(Pharmacokinetics and Pharmacodynamics) [83], where the equation parameters are statis-
tically derived from experimental work, and the pharmacokinetics is modeled only locally
within a spatial scale of a cell; iii) PBPK (physiologically-based pharmacokinetics) [84],
where pharmacokinetics is modeled globally for the whole body but by considering each
organ as a single compartment where the drug is homogeneously distributed.
Especially, nanomedicine-enabled TDDSs require new pharmacokinetic models where
the particle propagation processes within the body are described in greater precision at a
much smaller time and space resolution, and in a tractable manner, whereas the aforemen-
tioned models account for particle propagation only at the spatial resolution of organs and
the time scale of days. Moreover, the existing models are not sufficiently scalable and are
not customizable to the patients and their specific diseases [82].
To tackle the aforementioned problems, we propose a TDDS pharmacokinetic model
based on the abstraction of Molecular Communication (MC), a recently developed paradigm
in communication theory that defines information exchange through the emission, propa-
gation, and reception of molecules. In [57], we developed an MC model to calculate the
time-varying blood velocity in any location of the cardiovascular system, and to predict the
propagation of the drug-loaded particles due to advection and diffusion in the blood flow.
In this chapter, by stemming from our previous work, we develop a TDDS pharmacoki-
netic model able to predict the propagation of the particles by taking into account other
specific physicochemical processes, as well as abnormal health conditions. Through the
MC paradigm, we consider the following physicochemical processes:
• The advection process, which represents the transport of particles due to the blood
velocity.
• The diffusion process, which corresponds to the Brownian motion of particles
• The absorption process, which quantifies the particles absorption through tissues
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surrounding the blood vessels [85].
• The reaction process, which is a consequence of the degradation of particles in the
blood [86].
• The adhesion process, which accounts for other biomolecules binding to the drug-
loaded particles. The adhesion process is one of the main adverse effects to the
performance of the TDDSs [87].
In the proposed pharmacokinetic model, we also account for the effects on the drug
pharmacokinetics of cardiovascular diseases, which include blood vessel leakage, e.g., due
to tumors, and rigidity, e.g., due to arteriosclerosis. These effects are analytically con-
sidered in the proposed pharmacokinetic model, and are shown to greatly affect the drug
particle distribution through numerical evaluations of the pharmacokinetic model and the
biodistribution estimation.
In the proposed pharmacokinetic model, we also account for the effects on the drug
pharmacokinetics of cardiovascular diseases, which include blood vessel leakage, e.g., due
to tumors, and rigidity, e.g., due to arteriosclerosis. These effects are analytically con-
sidered in the proposed pharmacokinetic model, and are shown to greatly affect the drug
particle distribution through numerical evaluations of the pharmacokinetic model and the
biodistribution estimation.
By stemming from the proposed MC-based pharmacokinetic model, we propose a
method to estimate the drug biodistribution. We propose to characterize the presence of the
drug at the delivery location through communication engineering metrics, namely, channel
delay and path loss, analytically derived from the proposed pharmacokinetic model. The
channel delay corresponds to the time needed by the drug particles to reach their peak
concentration at the delivery location after they are injected, while the channel path loss
is the ratio of the drug particles that effectively reach the delivery location over the drug
particles that were initially injected. In addition, we also demonstrate that the proposed
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pharmacokinetic model allows to analytically estimate the drug accumulation in the rest of
the body.
The proposed MC-based pharmacokinetic model is validated through finite-element
simulations on COMSOL, which consider 3D Navier-Stokes and advection-diffusion-reaction
equations to simulate the drug propagation in a time-varying blood flow through a 3D
model of a blood arterial network. The proposed MC-based pharmacokinetic model proves
to be in good agreement with the results of the simulation, therefore reproducing similar
results with analytical expressions, which do not require the computational complexity of
the finite-element simulations. Additionally, numerical results are provided for the biodis-
tribution estimation in different health scenarios, namely, in the presence of arteriosclerosis
and tumor-induced blood blood vessel leakage. Through these results, we show that the
transport and kinetic properties are important factors influencing the pharmacokinetics of
the drug-loaded particles.
Finally, by stemming from the proposed model, we detail a procedure to analytically
express the optimal drug injection rate given a target drug delivery rate. For this, we sup-
pose that the healing of the disease requires an objective drug delivery rate, and that the
drug injection and delivery locations are known. The proposed pharmacokinetic model is
then applied to analytically obtain the optimal drug injection rate.
The rest of the paper is organized as follows. In Section 5.2, we mathematically de-
scribe the pharmacokinetic model based on the MC abstraction of the physicochemical
processes in the drug-loaded particle propagation, namely, advection, diffusion, reaction,
absorption, and adhesion. Moreover, we incorporate in the pharmacokinetic model possible
cardiovascular diseases affecting the blood flow. In Section 5.3, we obtain the biodistribu-
tion estimation of the particles through the communication engineering metrics of channel
path loss and delay, and the expressions to compute the drug accumulation in the rest of
the body. Numerical results are provided for the biodistribution in different scenarios. In
Section 5.4, the validation of the MC-based pharmacokinetic model with multiphysics
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finite element simulation is presented. In Section 5.5, we apply the MC-based pharma-
cokinetic model to find the optimal drug injection rate that would achieve an objective
drug delivery rate at the delivery location. Finally, Section 6.8 concludes the paper with
comments about the validity of the model and the various factors influencing the perfor-
mance of TDDSs.
5.2 MC-based Pharmacokinetic Model
In this section, we mathematically describe the pharmacokinetic model of a TDDS
based on the analytical MC channel abstraction, which considers additional physicochemi-
cal processes in the particle propagation from the injection location to the delivery location,
in addition to the advection and diffusion processes already considered in [57].
The network of blood vessels is abstracted here as an MC network. Fig. 31 illustrates
the physicochemical processes in a blood network consisting of several blood vessels. un(t)
denotes the blood velocity in a blood vessel n, and t is the time variable. The drug prop-
agates in this blood network subject to an absorption with rate ρn, reaction with rate µn,
adhesion with an adsorption rate k+ and a desorption rate k−, diffusion with a diffusion co-
efficient D, and advection driven by the blood velocity. The drug propagation is abstracted
as an MC channel, and completely characterizes the relationship between the drug injection
rate and the drug delivery rate. The drug injection rate is the MC signal transmitted at the
inlet of the blood vessel and the drug delivery rate is the MC signal received at the outlet of
the blood vessel. This is achieved by a time-varying impulse response h(ρn,µn)(n) (t, τ), where
τ is a time variable, for every blood vessel n (n = 1, 2, . . . , 7). The MC link channels are
cascaded to obtain an MC path, which provides the relationship between the drug injection
rate x(t) and the drug delivery rate y(t), through the time-varying impulse response for the
path channel, denoted, e.g., by h(ρ1,µ1,ρ2,µ2,ρ4,µ4)(1,2,4) (t, τ) for the cascade of MC links 1, 2, and 4
as shown in Fig. 31.
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In Section 5.2.1, we present how a blood vessel is abstracted as an MC link. In Sec-
tion 5.2.2, we describe how the physicochemical processes between the drug particles and
the body can be modeled by combining MC links. Finally, in Section 5.2.3, the modeling
of cardiovascular diseases using equivalent circuits is proposed.
5.2.1 Molecular Communication Link Model
We found in [57] that the drug injection rate x(t) and the drug delivery rate y(t) in the blood




x(τ)h(ρn,µn)(n) (t, τ)dτ . (121)
Due to the fluctuations in the blood flow, the impulse response of the system depends
on the state of the blood flow at the time of the injection, therefore the system is not linear
time-invariant (LTI). The response of non-LTI systems cannot be expressed in the form of a
convolution operation. For the aforementioned reasons, the expression in (121) is different
from a convolution. We derive the analytical expression of the time-varying impulse
response of the MC link n, as follows:

















where t′ is the time integration variable.
• σ2n(t, τ) is a function of the effective diffusivity Dn(t) as follows:




• µn is a characteristic of the reaction process, and represents the rate of reaction be-
tween the particles and the blood.
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Figure 31. Scheme of the MC modeling of TDDSs pharmacokinetics.
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In the following, we provide the expression of the apparent velocity vn(t) and the effective
diffusivity Dn(t) for advection-diffusion (Section 5.2.1.1), absorption (Section 5.2.1.2), and
adhesion (Section 5.2.1.3).
5.2.1.1 Advection-diffusion Case (No Reaction)
When the reaction process is absent, and only the advection-diffusion is occurring, the
apparent velocity in the case of no reaction vnonen (t) and the effective diffusivity in the case
of no reaction Dnonen (t) are: 
vnonen (t) = un(t)






which is a result we derived in [57].
5.2.1.2 Absorption Case
When there is absorption due to the tissues that surround the blood network, the apparent
velocity in the case of absorption vabsorptionn (t) and the effective diffusivity in the case of















When adhesion to the proteins in the blood plasma or to the blood vessel walls is occurring,
the apparent velocity in the case of adhesion vadhesionn (t) and the effective diffusivity in the







































Section 5.4.2 provides numerical values for the cross-sectional average blood velocities
of three blood vessels, obtained using the transmission line method described in [57].
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5.2.2 Molecular Communication Path Model
The MC channel model of a path (n; n = 1 . . .N) where n is the index of a link n, is obtained




x(τ)h(ρn,µn;n=1...N)(n;n=1...N) (t, τ)dτ , (128)









Through the HTM method [35], we can find analytical solutions of the end-to-end impulse
response of TDDSs, as opposed to numerical solutions by finite-element models.
5.2.3 Disease Models with Equivalent Circuits
In this section, we present an equivalent circuit modeling of cardiovascular diseases, in-
cluding arteriosclerosis (rigid blood vessel model), and blood vessel leakage (leaky blood
vessel model).
A blood vessel is considered as a cylindrical elastic tube with radius rn and length ln, and
modeled as an electrical circuit, whose electrical components are related to the geometry
of the blood vessels. A healthy blood vessel n possesses three electrical components. First,
a resistance Rn, which is related to the blood viscosity and the diameter of the blood vessel.
Second, an inductance Ln, which is related to the blood inertia, that is how a difference in
blood pressure causes a difference in blood flow. Third, a capacitance Cn, which measures
the blood vessel elasticity. We give below the expression of the electrical components based
on their physiology [57].





where ν is the blood viscosity.
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where η is the blood density.
5.2.3.1 Rigid Vessel Model
The elasticity of a blood vessel is an important parameter in the success of drug delivery.
There have been studies to show how abnormal elasticity affects drug propagation [90].
Blood blood vessels can become rigid because of aging and diseases such as arteriosclero-
sis [91].
For a rigid blood vessel, we model the change in elasticity using an arterial elasticity
factor, which measures the ratio between normal elasticity and rigid elasticity. We retain
the same electrical components as in the healthy blood vessel model, except for the capac-
itance, which is now equal to:
Cn =
πrn2
FC(a1 exp(−a2rn) + a3)
, (133)
where FC is the arterial elasticity factor (FC = 1 for a healthy blood vessel, FC = 0 for
a completely rigid blood vessel). a1 = 1.34 × 107g/(s2.cm), a2 = 22.53cm−1, and a3 =
5.77 × 105g/(s2.cm) are statistical parameters obtained from physiological measurements
[37].
5.2.3.2 Leaky Vessel Model
The leakage of a blood vessel is modeled by an equivalent conductance, which is related
to how easy it is for a fluid to leak from the blood vessel. We retain the same electrical
components as for the healthy blood vessel case, but we add an additional conductance Gn





where FL is leakiness factor, which compares the leakage to the conductance of the healthy
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Figure 35. Blood velocities at a tree of small blood vessels with a branch suffering from arteriosclerosis.
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Figure 36. Effect of the diffusion coefficient D and the absorption rate ρn on the channel delay.
Fig. 32 shows the equivalent electrical circuit components for a blood vessel in dif-
ferent conditions such as a healthy condition, arteriosclerosis, and blood vessel leakage.
By defining electrical equivalents of diseased blood vessels, the blood velocities are cal-
culated by using the transmission line theory method presented in [57], after substituting
the expressions of the conductances and the capacitances for healthy blood vessels with the
expressions in (133) and (134), respectively. For the numerical results, the inner iliac blood
vessel [55] was chosen, and the properties of three of its children blood vessels, denoted as
(3, 6, 7) in Fig. 33, Fig. 34, and Fig. 35, respectively, have been modified according to the
considered disease condition.
In Fig. 33, we observe that in a healthy arterial tree, the blood velocity tends to dampen
slowly as we go farther from the root of the blood vessel. In the case of a blood vessel
leakage, as illustrated in Fig. 34, this trend is not observed, where we can see that the
blood velocity may increase in some daughter blood vessels, since the resistance is reduced.
Fig. 35 shows the extreme case where a portion of the arterial tree is affected by a severe
arteriosclerosis. In that case, the diseased blood vessels exhibit a highly oscillatory blood
flow.
The method introduced in this section can be applied to model the drug propagation in
any location of the arterial network.
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5.3 Biodistribution Estimation
The biodistribution is the study of the location and the quantity of the drug that is
accumulated in the delivery location and the rest of the body, whether in the blood vessels,
their surround tissues, or reacting with elements of the blood plasma. In this section, we
estimate the biodistribution of TDDSs using the MC paradigm through the definition of
two MC metrics, namely, the channel delay and the channel path loss. In Section 5.3.1, the
channel delay is the time needed by the drug particles to reach their peak concentration at
the delivery location after they are injected in the body. In Section 5.3.2, the channel path
loss is the proportion of the injected particles that reach the delivery location despite the
blood vessels branching, reaction, adhesion, and absorption. Finally, in Section 5.3.3, the
drug accumulation in the rest of the body is expressed analytically using the MC model.
5.3.1 Channel Delay to the Delivery Location
We define the delay for a TDDS as the time required by injected molecules to reach their
peak concentration at the delivery location, which is a definition typically used in biodis-
tribution. Another definition of delay used in biodistribution studies is the half-life of a
drug [92], which is only meaningful for drugs undergoing an exponential decay. The def-
inition we choose is more general than half-life, and can provide more information about
the toxicity, potency, and elimination rate of the drug, since these properties depend on the
overall time spent by the majority of the molecules between the injection location and the
delivery location.








h(ρn,µn;n=1...N)(n;n=1...N) (t + τ, τ)dτ , (135)
where h(ρn,µn)(n;n=1...N)(t, τ) is the time-varying impulse response with injection starting at the time
τ, and T is the heartbeat period.
Since the channel is time-varying and the blood flow changes periodically, the injected
drug particles will be delivered with a different channel delay at the delivery location de-
pending on the blood velocity that was experienced by the body when they were injected.
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We consider the ambiguity in knowing the blood velocity at the time of injection by av-
eraging over the channel delays for all possible blood velocity values that the body may
experience.
The definition of the delay as the average is only acceptable for long propagation times.
However, it is acceptable to use the delay as the average value to compare several drug
delivery systems that are within the same flow, and propagation length conditions. The
standard deviation (or error) in the delay calculation can be highly variable for the scenario
where the propagation time is low. If the blood velocity period is higher than the time it
takes for the molecules to reach the delivery location, then the error can be as much as in
the order of 100%. However, if the blood velocity period is small compared with the delay,
then the error is negligible, which means that the injection time is not critical.
5.3.2 Channel Path Loss at the Delivery Location









where h(ρn,µn)(n;n=1...N)(t, 0) is the time-varying impulse response, which we defined in Sec-
tion 5.2.2 with injection starting at the time τ = 0. This relationship comes from the
fact that the impulse response is the probability density of a single particle arriving at a
specific location and time. The log-scale is used because about half of the particles are
lost at every blood vessel bifurcation, which makes the particle loss follow an exponential
trend. In Fig. 36, we see the effect of the blood velocity, the drug diffusion coefficient and
the reaction rate on the channel delay. In the numerically evaluated scenario in Fig. 37 ,
we observe that the increase in the drug diffusion coefficient contributes in increasing the
delay of the channel, while the effect of the absorption rate contributes in decreasing the
delay.
In Fig. 37, we observe that reaction and absorption have similar consequences on the
channel path loss. For the absorption, we see that the higher the absorption rate the smaller
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Figure 37. Effect of the absorption rate (ρn) and the reaction rate (µn) on the path loss.
the delay, which may seem counterintuitive. The reason behind the reduction in delay for
increased absorption is that the absorption reduces the number of particles in the blood that
are in proximity of the walls, which are the slowest moving particles, thus increasing the
average velocity of all the particles.
5.3.3 Drug Accumulation in the Rest of the Body
Using the time-varying impulse response, we can calculate the proportions of the drug
particles that are either still in the blood, have been absorbed by the surrounding tissues, or
have reacted with the blood plasma.















































































Figure 38. Effect of cardiovascular diseases on drug distribution.














Therefore, we can use the MC paradigm to predict where the drug is going to accumu-
late based on the physiological parameters of the drug delivery system and the body. As
presented in Fig. 38, the blood vessel conditions cause some variance in the biodistribution.
This is moderately important in leaky blood vessels, but is very important in the case of
blood vessels affected by arteriosclerosis.
5.4 Multiphysics Finite-Element Validation
In order to obtain a pharmacokinetic model of TDDSs, we made the following assumptions:
continuous concentration at the bifurcation, Poiseuille flow, Taylor dispersion approxima-
tion, perfectly cylindrical geometry, and infinite-length blood vessels. Using finite-element
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analysis, the developed model is validated realistically in a 3D geometry and assuming
physical equations in their full forms. In this section, we present the validation of the MC
model of TDDSs by simulation using finite-element analysis. We describe the geometry
of the simulated system, its governing physical equations, and how the parameters of the
analytical model have been mapped to parameters of the finite-element analysis.
Finite element analysis is a numerical method used to solve partial differential equa-
tions [9] that underlie the behavior of complex physical systems, including mechanical and
chemical transport systems. Finite element analysis has several advan- tages compared
with analytical models. First, finite element analysis allows to simulate objects of arbitrar-
ily complex 3D geometry. This is especially required for biological objects such as blood
vessels which have an imperfectly cylindrical shape and bifurcation shapes. Second, finite
element analysis makes it possible to simulate the interaction of different physical phenom-
ena, such as the interaction of the blood vessel walls, the blood flow, which is governed by
fluid mechanics, and the chemical transport of drugs. The validation is carried out using
COMSOL®1, a finite element simulation software package.
The following aspects of a drug delivery systems are considered in the simulation as
follows:
• Blood flow: the validation is performed using a 3D model of a blood arterial network
under realistic conditions. The blood flow, which is the main driving force of the
drug propagation, is simulated using the 3D Navier-Stokes equations in the station-
ary domain. In contrast with existing pharmacokinetic models which are based on
unrealistic assumption of having a constant blood flow [93], the drug is propagated
through a time-varying blood flow. The blood flow boundary conditions in the ar-
terial networks are estimated based on the realistic transmission line theory which
provides results in very good agreement with MRI measurements of blood flow in a
human [57].
1COMSOL® is a registered trademarks of COMSOL AB.
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• Geometry: in the simulation, we assume cylindrically-shaped small blood vessels,
which is in agreement with the physiological observations [94]. Large blood vessels
and anomalously shaped blood vessels can be considered with little modifications.
• Drug transport: Through the COMSOL simulation, we observe that the MC model
based on Taylor dispersion is a good approximation of particle transport in blood and
that, therefore, higher-order approximations [95] which will make the expression of
the analytical solution more complex are not needed.
• Drug kinetic interactions: the binding is considered by adding a linear reaction term
to the 3D advection-diffusion equation. The absorption is simulated as a boundary
condition on the blood vessel walls where the particles are not perfectly bouncing
but proportionally lost at the surface. The linear first order kinetics for binding and
absorption are common for particles [96]. We assume that no other kind of binding
occurs and that particles are at a sufficiently low concentration to avoid non-linear
binding kinetics.
5.4.1 Topology
For the numerical evaluation of the model, the topology information was derived from the
MRI scan of a young male individual, which is available from [55]. However, the available
MRI scan anatomical information only covers the large blood vessels. An algorithm that
represents the small blood vessels as a fractal tree rooted in the extremity of the large blood
vessels was used to obtain the topology of the studied area, in a similar way as in [57]. The
numerical values and structure of the topology are listed in this chapter and included in
Table 2 to simplify the reproduction of the results. In fact, a blood network was considered,
consisting of interconnected blood vessels n, where n is the blood vessel index (n = 1 . . . 7).
The parent blood vessel 1 bifurcates into two blood vessels, the daughter blood vessel 2 and
the daughter blood vessel 3, and so on. The blood vessel n has a radius rn and a length ln, for
n = 1 . . . 7. We have r1 = 0.5 mm, r2 = 0.45 mm, r3 = 0.3 mm, r4 = 0.40 mm, r5 = 0.23 mm,
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(a) t = 46 ms. (b) t = 92 ms.
(c) t = 138 ms. (d) t = 184 ms.
Figure 39. Evolution of the drug propagation in a tree of blood vessels showing the transport of the
injected drug particles from the inlet of the tree of blood vessels to the outlets of the branches, at
different times t.
r6 = 0.27 mm, and r7 = 0.18 mm for the radii, and l1 = 25 mm, l2 = 22.5 mm, l3 = 15 mm,
l4 = 20 mm, l5 = 11.5 mm, l6 = 13.5 mm, l7 = 9 mm. These dimensions are chosen to be
physiologically plausible [55]. According to the physiological data about the size of blood
vessels, all types of veins and blood vessels have an interior radius of the blood vessels that
is very small compared to the length. This is supported quantitatively in the human and
animal physiology literature such as in [55]. In particular, the work in [55] mentions that
the length of blood vessels is 25 times the size of their diameters with a standard deviation
equal to 5. This work also uses straight cylinders to model blood propagation in blood
vessels, which occurs at a faster scale than drug diffusion.
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Table 2. Blood network boundary conditions numerical values
k 0 1 2 3
qk,1 1.3 · 10−4 2.9 · 10−3 −1.8 · 10−4 1.6 · 10−5
pk,1 1.3 · 10−4 1.7 · 10−4 5.0 · 10−5 −6.3 · 10−5
qk,1 1.3 · 10−4 2.9 · 10−3 −1.8 · 10−4 1.6 · 10−5
pk,2 1.3 · 10−4 1.7 · 10−4 4.9 · 10−5 −6.2 · 10−5
qk,2 1.3 · 10−4 2.8 · 10−3 −1.7 · 10−4 1.6 · 10−5
pk,3 7.3 · 10−5 9.6 · 10−5 2.8 · 10−5 −3.5 · 10−5
qk,3 7.3 · 10−5 1.6 · 10−3 −9.8 · 10−5 8.8 · 10−6
pk,4 1.3 · 10−4 1.7 · 10−4 4.9 · 10−5 −6.1 · 10−5
qk,4 1.3 · 10−4 2.8 · 10−3 −1.7 · 10−4 1.5 · 10−5
pk,5 7.2 · 10−5 9.5 · 10−5 2.7 · 10−5 −3.5 · 10−5
qk,5 7.2 · 10−5 1.6 · 10−3 −9.6 · 10−5 8.6 · 10−6
pk,6 7.2 · 10−5 9.5 · 10−5 2.7 · 10−5 −3.5 · 10−5
qk,6 7.2 · 10−5 1.6 · 10−3 −9.6 · 10−5 8.6 · 10−6
pk,7 4.0 · 10−5 5.3 · 10−5 1.5 · 10−5 −1.9 · 10−5
qk,7 4.0 · 10−5 8.9 · 10−4 −5.4 · 10−5 4.9 · 10−6
5.4.2 Blood Velocity Boundary Conditions
The multiphysics finite-element simulation requires the definition of boundary conditions,
which are values defined at the surfaces of the blood network, to find the numerical solu-
tions that satisfy the physical equations. We use five boundary conditions which are defined
at the inlet (n = 1) and the outlets (n = 4, 5, 6, 7) of the blood network as shown in Fig 39.
Thus, there are five boundary conditions which are the blood velocity u1(t) at the inlet of
the network, and the blood velocities un(t) for the blood vessels n, for n = 4, 5, 6, 7, re-
spectively. The numerical values for the boundary conditions have been obtained using the
transmission line model developed in [57]. Since the boundary conditions are time-varying




pk,n sin(kω0t) + qk,n cos(kω0t) , (141)
where ω0 = 2π/T is the radial sampling frequency, K is the number of samples, and the
coefficients {pk,n; k = 0 . . .K − 1} and {qk,n; k = 0 . . .K − 1} are the even and odd Fourier
coefficients, respectively.
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5.4.3 Drug Propagation Initial Conditions
The drug propagation initial conditions describe the initial values of the drug concentration
in the blood network at time t. We express the initial drug concentration c(x1, y1, z1, t) in
the blood vessel n as a function of the Cartesian coordinates, with the origin at the center
of the inlet of the blood vessel 1, and the ~x1 axis along the longitude of the blood vessel.
We approximate the drug injection impulse with a Gaussian function with a very small
variance, which we can write as follows:







where x1 is the Cartesian coordinate along the longitude of the blood vessel 1, σ1 is the
standard deviation of the impulse, and c0 is the initial concentration of particles. The
justification of a drug injection as a Gaussian function rather than a Dirac delta function
is essential to obtain the resolution of partial differential equations using using a finite-
element methods solver [97].
5.4.4 Validation Results
The impulse responses h(ρn,µn;n=1...N)(n;n=1...N) (t, τ) are evaluated at the outlets of the blood vessels n
where n = 1 . . . 3. We evaluate the impulse response h(ρn,µn)(n) (t, τ) as:






c(x, y, zn, t)dxdydz ,
where On denotes the outlet of the blood vessel n, S On is the surface area of On, M(x, y, zn)
is a point in On, and c(x, y, zn, t) is the concentration at the time instant t and the point with
the coordinates (x, y, zn).
The simulations were performed using COMSOL on a desktop machine with a total
computation time of 2 h 57 min to build the map of blood velocity and for the propagation of
drug particles, for a simulation duration Tsim = 0.25 s. Table 2 lists the Fourier coefficients
that have been used in the multiphysics finite-element calculations.
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Figure 40. Comparison between the impulse responses obtained by the MC model and the impulse
responses obtained by the multiphysics finite-element simulation technique for different delivery loca-
tions at the outlet of the blood vessels 1, 4, and 5, respectively.
In Fig. 40, we compare the impulse responses obtained by multiphysics finite-element
simulation with the analytical results obtained using the MC model described in Sec-
tion 5.2, where we use the following values for the diffusion coefficient D = 10−8 m2/s
and the absorption rates (ρn = 1e − 5; n = 1 . . . 7). We compare the results for all three
blood vessels 1, 4, and 5, and we notice in the three cases that there is good agreement
between the values generated through the simulation and the model.
5.5 Drug Injection Optimization
In this section, we aim to propose a solution to the optimization of the drug injection in or-
der to achieve a desired drug delivery rate, based on the MC-based pharmacokinetic model
presented in Section 5.2. In order to obtain efficient drug delivery systems, the timing and
location of the drug particles are crucial. The diseased region needs to receive the particles
at the right time and in the right quantity. When the particles are injected by systemic ad-
ministration, the drug particles can be lost in blood vessel bifurcations, absorbed by blood
vessels, and mixed with the blood due to diffusion. Fig. 41 shows a scheme of the injection
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Figure 41. Scheme of the injection rate rate optimization for a desired drug delivery rate.
is found giving exactly the desired delivery rate with minimal error.
In the following, we present a method to find the optimal inject rate based on the de-
sired drug delivery rate, the physiological parameters of the body, the drug properties, the
injection location and the delivery location.
We consider a disease that requires a specific drug delivery rate that will make the
healing effective, with just a minimal number of drug particles, and below the level that
causes toxicity. We suppose that a desired drug injection rate is given by a time-varying
function x(t), which describes the drug concentration rate at every time t in the injection
location.
Using the pharmacokinetic model in Section 5.2, we obtain a channel model character-
ized by a time-varying impulse response h(ρn,µn;n=1...N)(n;n=1...N) (t, τ) which relates the drug injection




h(ρn,µn;n=1...N)(n;n=1...N) (t, τ)x(τ)dτ . (144)
Here, our objective is to find the optimal drug injection rate x∗(t), such that the obtained
drug delivery rate y∗(t) is as close as possible to the drug delivery rate y(t). This is expressed
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by:
x∗(t) = arg min
x(t)
‖y(t) − y∗(t)‖ . (145)







h(ρn,µn;n=1...N)(n;n=1...N) (t, τ)x(τ)dτ − y
∗(t)
∥∥∥∥∥∥ ,
where h(ρn,µn;n=1...N)(n;n=1...N) (t, τ) is the time-varying impulse response that characterizes the drug
propagation from the injection location to the delivery location.




h(ρn,µn;n=1...N)(n;n=1...N) (t j, τ)x(τ)dτ . (147)
xi is defined as:
xi = x(iTs) , (148)
where i, j = 1 . . .K, K is the number of samples, and Ts is the sampling period. With







h(ρn,µn;n=1...N)(n;n=1...N) ( jTs, τ)dτ . (149)




h(ρn,µn;n=1...N)(n;n=1...N) (ti, τ)dτ . (150)






i, j . (151)
Thus, the problem can be written in matrix notation as
y = H(ρn,µn;n=1...N)(n;n=1...N) x , (152)
where y =
[
y j; j = 1 . . .K
]′
is a K-dimensional vector whose elements are samples of the
desired delivery rate, x = [xi; i = 1 . . .K]′ is a K-dimensional vector whose elements are
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samples of the optimal injection rate, and H(ρn,µn;n=1...N)(n;n=1...N) is the square matrix of size K-by-K,
whose components are defined in (150), and [.]′ is the vector transpose operator.
The matrix H(ρn,µn;n=1...N)(n;n=1...N) is supposed to be invertible. In case the matrix is not invertible,
the linear matrix inequality approach as proposed in [98] can be directly adapted to the MC
model to find the optimal injection rate.










is the inverse of the matrix H(ρn,µn;n=1...N)(n;n=1...N) .










According to the Nyquist criterion [99], the sampling period should satisfy Ts < 12B , where
B is the bandwidth of the time-varying impulse response of the system. The sampling
period depends on the blood velocity and the characteristic time scale of the advection-
diffusion. For the simulations, a value of Ts = 15.645 ms, which is the sampling period of
the measured blood cardiac flow input was chosen. This is much shorter than the charac-
teristic time scale of the advection-diffusion.
5.6 Conclusions
In this chapter, we propose to apply the abstraction of the MC paradigm to address im-
portant problems in TDDSs, namely, modeling the drug pharmacokinetics, estimating the
biodistribution, and optimizing the drug injection rate. The MC abstraction allowed to ob-
tain an analytical pharmacokinetic model that accounts for various physicochemical pro-
cesses in the particle propagation, and takes into account the impact of cardiovascular dis-
eases. By stemming from the pharmacokinetic model, we proposed to use communication
engineering metrics to estimate the drug biodistribution at the delivery location, while an-
alytical expressions are obtained to estimate the drug accumulation in the rest of the body.
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We have favorably compared our pharmacokinetic model with multiphysics finite-element
simulations of the drug propagation in the arterial system, and provided numerical results
for the drug biodistribution in different scenarios. We also proposed a procedure to optimize
the drug injection rate according to a desired drug delivery rate through the pharmacoki-
netic model when the injection location and delivery are known.
The pharmacokinetic model presented in this chapter does not take into account parti-
cles that continue their propagation after having circulated the entire cardiovascular system.
This is justified by the fact that heart and veins tend to significantly disperse the particles,
therefore favoring their accumulation over their recirculation in the cardiovascular system.
A possible future extension of this work could also include these effects in the pharma-
cokinetics through a stochastic model derived from an MC noise abstraction, as presented
in [100].
The results presented in this chapter can support the future design of intra-body MC
networks [101]. In fact, the developed pharmacokinetic model has the potential to be used
to predict the propagation of MC signals in the human body undergoing several transport
and kinetic processes. With regards to the communication performance of such a system,
the theoretical limits of the amount information that can be reliably transmitted by MC
over the blood vessels has been studied in [100]. By defining the encoding and modula-
tion schemes for MC in the cardiovascular system, the achievable bit error rates can be
evaluated.
In conclusion, the proposed abstraction of a TDDS with the MC paradigm provides a




MOLECULAR COMMUNICATION SYSTEM MODEL FOR
ANTIBODY-MEDIATED DRUG DELIVERY SYSTEMS
6.1 Motivation and Related Work
Antibody-mediated Drug Delivery Systems (ADDS) are at the forefront of current ther-
apeutic research [5]. The system uses artificial molecules that are constructed from bi-
ological materials to build and engineer drug delivery systems. They are inspired by the
naturally occurring autoimmune mechanisms that enable the human body to diagnose itself
and destroy the exact source of the disease, in an adaptive and constructive fashion. The
versatility in engineering ADDS and their attested clinical success open up the possibility
to develop sophisticated therapeutic strategies to effectively target diseases [102]. Fig. 2 il-
lustrates the elements of the ADDS. The drug injection occurs in the blood vessels, and the
drug delivery occurs in the extracellular matrix. The drug injection introduces antibodies
which are transported by the blood flow and diffused through the tissues. The blood ve-
locity field transports the antibodies and some of them diffuses through the vascular walls
into the tissues. Upon arriving at the diseased cell, the antibodies bind with the antigens
located on the surface of the diseased cell at the antigen-antibody binding site. The antigen-
antibody kinetics promotes the selective targeting of the diseased cells without affecting the
healthy cells. The interplay of these different transport and kinetic processes contributes to
the performance of the ADDS in maximizing the delivery of the antibodies to the diseased
cells.
In this chapter, Molecular Communication (MC) paradigm [2], where the informa-
tion is conveyed through molecules, is proposed to model the ADDS while considering
the unique properties of antibodies and the possibilities that they offer. This new model
will address the short comings of Physiologically-based Pharmacokinetics (PB/PK) mod-
els that have been proposed for ADDS propagation in the literature. PB/PK methods suffer
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from many limitations that make them inapplicable to helping the current state-of-the-art in
nanomedicine [24] [25]. The issue with the PB/PK model is that the diseases that are meant
to be targeted with ADDS, such as tumors, are highly localized and grow quickly, and this
model does not provide enough spatial and temporal accuracy to assess the efficiency of
the ADDS. Also, by modeling complex molecules for the first time in the area of MC, this
work addresses the limitations in the existing MC modeling works [103] [12].
By using the MC-ADDS paradigm, a bottom-up approach of modeling the propagation
of antibodies is proposed where the appropriate structure of the antibody is determined,
and from that propagation around the body is predicted. The MC-ADDS model solves
this problem by providing mechanistic models, based on the laws of biophysics instead
of empirical observations, and minimizing the need for parameters estimation. This will
provide higher spatial and temporal resolution tracking of the drug propagation in the micro
and millisecond scale, while being scalable to lower and higher resolutions with small
changes to the system model. In MC-ADDS, the human body is modeled as a complex
network of blood vessels and tissues where the transmitted signal is modulated by the
antibody concentration at the injection location, which is the location of the body where
the syringe is injected, and the propagation in the body is represented with simple analytical
models, directly derived from the physiology of the patient and the chemical and electrical
structure of the antibody molecule. Sec. 6.7 will show that the MC-ADDS modeling allows
the calculation of the end-to-end impulse response of the system, and evaluating which
kinetic processes are impeding the drug delivery.
In particular, the main contributions of this work are as follows:
• Modeling an end-to-end abstraction of ADDS as an MC channel: The abstracted
MC channels the ADDS into three different channels corresponding to different parts
of the body. These three different channels include the vascular, extracellular, and
antigen binding channels. Numerical evaluations are conducted for each channel to
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Figure 42. The MC abstraction of the ADDS.
• Determining an optimized shape for the antibody molecular structure: The
movement of the antibodies with the blood flows is modeled based on their 3D struc-
ture. The optimized geometrical structure for the antibodies is determined based on
the diffusion behavior, as well as their successful binding process to the diseased
cells. The model considers the chemical components within the blood that affects the
antibody, as well as the electrochemical properties of the antibody-antigen complex.
• Validation of the end-to-end ADDS MC channel: Validations of the ADDS is
conducted using both analytical MC modeling and comparison to the COMSOL®1,
finite-element simulations. The comparison showed strong agreement between the
MC models and the COMSOL® simulations.
The MC-ADDS modeling will provide a clearer understanding of the mode of operation
of antibodies, and enable the development of innovative methods to guide the engineering
of verifiable and safe antibody mediated therapies. This includes the design and engineer-
ing of the drug structure [104] [105], mode of administration, and dosage optimization [6].
1COMSOL® and COMSOL Multiphysics® are registered trademarks of COMSOL AB.
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This opens up the possibility to optimize the properties of the ADDS to achieve a desired
therapeutic effect, by determining the drug injection rate in terms of drug dosage concen-
tration, the timing of the dosage, and the location of injection, thus maximizing the safety
and success of ADDS and minimizing the costs [7]. The second motivation behind the use
of MC-ADDS modeling, is to understand the physicochemical interactions between ADDS
and the body, which are more complex than in PDDS. For example, ADDS undergo electro-
static forces within the Extracellular Matrix (ECM) due to negatively charged proteins [8].
These electric forces significantly affect the intercellular transport, antigen binding, and the
absorption of the ADDS by the cells.
The rest of the paper is organized as follows: in Sec. 6.2, we explain the abstraction
of the ADDS through the MC paradigm, the objectives, and principles of this approach.
Sec. 6.3 presents the MC-ADDS Vascular Channel Model, which describes the MC ana-
lytical model of ADDS transport through the blood vessels, taking into account the roles
of tissue absorption, and the plasma binding. Sec. 6.4 introduces the MC-ADDS Extracel-
lular Channel Model, which is the MC analytical model of ADDS transport through the
extracellular matrix (ECM), taking into account the role of ECM protein binding. Sec. 6.5
presents the MC-ADDS Antigen Binding Channel Model which is developed through the
MC paradigm, by incorporating the electrochemical structure of the antibody molecule.
Sec. 6.6 defines the realistic COMSOL® Multiphysics model that was simulated to vali-
date the MC-ADDS model. Sec. 6.7 presents numerical results that were evaluated using
the MC-ADDS model and the COMSOL® Multiphysics simulation model. Sec. 6.8 con-
cludes the paper with the main outcomes of the MC-ADDS model and its prospective use
for the design and engineering of optimal ADDS.
6.2 MC Abstraction of ADDS
In this section, we present the MC-ADDS framework which abstracts the kinetics processes
that the antibody undergoes in different parts of the body as MC channels. In the context of
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communication theory, a channel is a communication medium characterized by an input-
output relationship. The combination of several channels together enables establishing a
network between several transmitters and receivers. The concept of channels is useful for
modeling, analyzing the performance, and optimizing a system regardless of the initial
conditions and input signals. As illustrated in Fig. 42, cascading the MC-ADDS channels
for each of these processes provides the end-to-end MC-ADDS channel from the location
where the antibodies are injected to the location where they are absorbed by the cells. The
drug injection is abstracted as a MC-ADDS transmitter and the drug absorption process is
abstracted as a MC-ADDS receiver. The antibody concentrations at different phases of their
propagation in the body are considered as MC signals, which are the inputs and outputs of
the following MC-ADDS channels:
• The MC-ADDS Vascular Channel models the propagation of the antibodies by
advection-diffusion through the force of the blood flow, the Brownian motion of the
antibodies in the blood, and the chemical binding with the molecules present in the
blood. The MC-ADDS vascular channel is characterized by a function hV(t). The
input signal to the MC-ADDS Vascular Channel is the ADDS Injection Concentration
x(t), defined as the concentration of antibodies in the injection location, which is
represented as follows:
x(t) = Ab(t)|Injection location . (155)
Ab(t) denotes the antibody concentration at the location of the injection at the time
t. The output from the MC-ADDS Vascular Channel is the Vascular ADDS Concen-
tration xV(t), which is defined as the concentration of antibodies in the blood as a
function of time t, as follows:
xV(t) = Ab(t)|Blood = hV(t) ∗ x(t) , (156)
where ∗ denotes the application of the impulse response hV(t) to the signal x(t).
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• The MC-ADDS Extracellular Channel models the transport of the antibodies through
the ECM. This channel is located between the vascular tissues and the surface of
the target cells, and is driven by the interstitial pressure between the blood vessel
walls and the target cells, the lymphatic flow, and the binding with the molecules of
the ECM. The MC-ADDS extracellular channel is characterized by a function hE(t).
The output signal of the MC-ADDS extracellular channel is the ADDS Extracellu-
lar Concentration xE(t), which is the concentration of antibodies in the ECM as a
function of the time t as follows:
xE(t) = Ab(t)|ECM = hE(t) ∗ xV(t) . (157)
• The MC-ADDS Antigen Binding Channel models the antigen-antibody binding
occurring at the surface of the target cell. The antigen-antibody binding is influenced
by the chemical affinity between the antigens expressed by the cell and the antibody,
as well as the physical forces exerted by the flow in the ECM. The MC-ADDS Anti-
gen Binding Channel is characterized by a function pB, which provides the output of
the MC-ADDS Antigen Binding Channel as the ADDS-Antigen Concentration y(t),
which is the concentration of antibodies bound to the antigens as a function of the
time t, given the ADDS extracellular concentration xE(t) as follows:
y(t) = AbAg(t)|Cell surface = pBxE(t) . (158)
AbAg(t) denotes the concentration of drug antibodies that are bound to antigens at
the location of the injection at the time t. pB is not time-varying because there is a
scalar relationship between the antibodies around the diseased cells and the antibod-
ies that bind to the antigens, in a steady state. y(t) is determined from the number of
antibodies that arrive around the surface of the diseased cells and the thermochemical
properties of the antibody-antigen binding.
This study will allow the optimization of MC-ADDS systems by appropriately design-
ing the antibody structure, shape, and chemical characteristics to maximize its ability to
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deliver its therapeutic effect where it is needed in a timely and efficient way.
6.3 MC-ADDS Vascular Channel Model
In this section, we derive an analytical model of ADDS vascular transport using the MC
paradigm. As illustrated in Fig. 43, the blood velocity field drives the transport of antibodies
in the vascular region, and also the antibodies diffuse randomly by Brownian motion. The
antibody molecule is characterized by two diffusion parameters, namely: the translational
diffusion coefficient DZ, and the radial diffusion coefficient DR. DZ is the parameter that
characterizes the diffusion of antibodies along the axis of the blood vessels. It is formally
defined as follows:
< z2(t) >= 2DZt , (159)
where the variable z is the translational coordinate of the antibody at the time t along the
axis of the blood vessels. The rotational diffusion coefficient DΘ is the parameter that char-
acterizes the diffusion of antibodies around their center. It is formally defined as follows:
< θ2(t) >= 2DΘt , (160)
where the variable θ is the angle of rotation of the antibody around its center.
6.3.1 MC-ADDS Vascular Channel Impulse Response
In classical MC, only one parameter, namely the diffusion coefficient D, is involved in the
transport of the molecules according to Ficks law by Brownian motion, but in the case of
ADDS, we will consider two parameters, namely the translational diffusion coefficient DZ,
which depends on the shape of the molecule, and the radial diffusion coefficient DR, which
depends also on the structure of the diffusion medium. Based on the general theory of
diffusion developed by Brenner [106], the irregular shape of molecules has an important
effect on their transport. In fact, the irregularity causes coupling between the rotational
and the translational diffusion parameters of complex molecules [107]. In addition, to
the translational-rotational anisotropy due to molecule shape, there is a translational-radial
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Figure 43. MC Abstraction of the ADDS
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anisotropy owed to the non-homogeneity of cells matrices where one direction is more
conducive to diffusion than the perpendicular direction. Examples of translational-radial
anisotropy include the transport of molecules in blood vessels, where the non-uniform
distribution of red blood cells affects the diffusion in the radial direction [108], and the
anisotropy in the ECM, where the cells are organized in a preferential direction, due to the
direction of mechanical forces, especially the ones involving connective tissues [109].
An MC-ADDS transport model is developed, enabling the prediction of the propagation
of antibodies in the vascular channel. This model is deterministic, but it should be noted
that there are many fluctuations in drug delivery systems in general owing to blood turbu-
lence, Brownian motion, and ligand-binding noise. These noise effects are explained in a
previous work [110], and can be applied to ADDS with little modifications. The impulse
response hV(t, τ) is obtained by cascading the impulse responses of each channel between
the drug injection site and the drug delivery site, which can be expressed as follows:
hV(t, τ) = hV1(t, τ) ⊗ . . . hVi(t, τ) · · · ⊗ hVL(t, τ) , (161)
where ⊗ denotes the operator for cascading the periodically time-varying impulse responses
of two systems as described in [57], hVi(t, τ) is the impulse response of the i-th MC vascular
channel, and L is the number of blood vessels located between the drug injection site and
the drug delivery site.
The transport process in the ECM is dominated by diffusion, although there is an ad-
vective transport due to the plasma excudating drug particles from blood vessels to the
lymphatic system in a directed way. However, the flow rate is so slow that the dispersion
due to advection is negligible. This coincides with clinical observation of antibody trans-
port [111]. The impulse response hVi(t, τ) is expressed for each MC vascular channel based
on the generalized anisotropic Taylor dispersion equation with absorption [112], with the
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vi(r, t) dt′ , (163)
• The variance of the antibody concentration increases with time and is expressed as
follows:
σ2i (t, τ) = 2
∫ t
τ
Di(t′) dt′ , (164)
where t and t′ are time parameters, The effective diffusion coefficient of the antibodies Di(t)
is expressed as follows [112]:











where DZ is the translational diffusion coefficient of the ADDS in the blood expressed in
(168), DE is the diffusion coefficient in the ECM, which is defined in Sec. 6.4, DR is the
radial diffusion coefficient due to anisotropy [108], ri is the radius of the vessel i, KV is the
non-specific binding equilibrium constant in the vascular channel, KE is the non-specific
binding equilibrium constant in the ECM, P f = 11+KV is a kinetic ratio, and the effective
blood velocity vi(t) is expressed as follows:
vi(t) = P f ui(t) , (166)
The non-specific binding equilibrium constant in the vascular channel can be calculated
from the non-specific binding energy ∆GV . This is calculated between the antibody and the




Figure 44. 3D structure of the antibody-antigen complex from the Protein Data Bank.









where ∆GV is the non-specific binding free energy between the antibody and the proteins
in the vascular channel, and R is the ideal gas constant. Finally, from (161) and (162), we
obtain the MC end-to-end impulse response of the ADDS.
6.3.2 MC-ADDS Vascular Channel Diffusion Coefficients
Here we introduce the model of the structure of the antibody which provides the reference
geometrical and electrochemical properties of the ADDS. These properties will be used to
derive the transport diffusion coefficients. The structural information is obtained from the
Protein Data Bank (PDB) [113], which hosts the tridimensional structural data of a large
number of biological molecules, including antibodies and their antigens. A visualization
of such a structure is presented in Fig. 44 which represents the atomic structure of the
antibodies as an assortment of balls occupying the volume of the atoms and their bonds with
other atoms. The PDB also includes the constituting chemical elements of the antibodies
and their electric charges. Among all the information provided by the PDB, in this chapter
we focus on the geometry of a molecule and its charges. Each element of the antibody is
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denoted as n, and the total number of elements constituting the antibody as N. An element
n possesses the following information:
• Cartesian coordinates, denoted by the vector (xn, yn, zn) with a given Cartesian center
O.
• Radius, denoted by the scalar value ρn, which measures half the distance between
one atom and its closest element.
• Charge, denoted by the value qn, which is the electric charge born by the element n.
These three types of information are sufficient to describe the kinetic parameters of the
antibody. In the following, we explain how these parameters are derived directly from the
PDB information.
In the literature [114] [115] [116], all MC and pharmacokinetic models contain infor-
mation on the basic shapes for the molecules such as spheres, and rarely ellipsoids and rods,
to capture the antibody propagation. Therefore, there is a need for a model that takes into
account the antibody shape and structure to predict the diffusion parameters of this small
molecule without any empirical choices. The antibodies come in different arbitrary shapes
and structures as can be seen in X-Ray structure analysis of this type of molecules [117].
As illustrated in Fig. 45, the antibody-antigen is composed of several beads. In general, the
antibodies are roughly Y-shaped molecules and consist of different heterogeneous regions
(light chain and heavy chain). The geometry of the antibody has an important effect on
its motion in the blood and tissues. The irregular shape can create arbitrary motions and
fluctuations that are different from the case of spherical nanoparticles that were considered
in PDDS.
The translational diffusion coefficient DZ and the rotational diffusion coefficient DΘ are
calculated as follows [118]: 
DZ = kBT3η tr(AZ) ,


































Figure 45. Bead model of an antibody.
where kB is Boltzmann coefficient, T is the temperature of the blood, η is the fluid viscosity,
tr (·) is the trace function of the matrices AZ and AΘ, which represent the translational
mobility tensor matrix and the rotational mobility tensor matrix [107]. These matrices AZ








































where m and n are the indices of two beads m and n in the molecular compound, as illus-
trated in Fig. 45, N is the total number of beads in the molecular compound, η is the fluid
viscosity, Rm,n is the center-to-center distance between two beads m and n, ρn is the radius
of the bead n, δm,n is the Kronecker delta function, Tm,n is the hydrodynamic tensor of the





 + ρ2m + ρ2nR2m,n
 I3 − Rm,nR†m,nR2m,n
 , (170)
where Rm,n is the distance vector between the beads m and n, {·}† is the transpose function
of the vector Rm,n, Rm,n is the center-to-center distance between two beads m and n, ρn is
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the radius of the bead n, ρm is the radius of the bead m, and Um is the skew matrix of the







where (xm, ym, zm) are the Cartesian coordinates of the bead with index m from an arbitrary







where (xn, yn, zn) are the Cartesian coordinates of the bead with index n from the origin O.
6.4 MC-ADDS Extracellular Channel Model
In this section, we present how the transport of ADDS in the ECM is modeled. Due the
differences between tissues in the body in terms of geometry, arrangement, tortuosity, and
density, the transport of ADDS is going to vary greatly in different parts of the body. The
parameter DE denotes the diffusion coefficient in a tissue surrounding a blood vessel. The
structure of the ECM is similar to foam. The antibodies will perform random motions and
collide with the membranes of the cells, thus affecting the distribution of their concentra-
tion. Using the theory of transport in porous media [120] [121], it is possible to derive an
expression for DE based on the characteristics of the tissue. In practice, it has been ob-
served that the transport in the ECM is largely dominated by the diffusion, therefore, we
neglect the transport due to interstitial pressure differences.
The MC-ADDS model of extracellular transport becomes a diffusion MC channel [103]










(4DE + KE) t
]
, (173)
where z is the coordinate towards the target cell, KE is the non-specific binding equilibrium
constant in the ECM, and DE is the diffusion coefficient in the ECM. The non-specific
binding equilibrium constant is a value that characterizes the rate of the first-order linear





As shown in Fig. 46, the diffusion coefficient DE is a function of following parameters
which can be estimated from the shape of the ECM:
• The porosity φ measures the propensity of the tissue components to allow the anti-
bodies to pass.
• The tortuosity κ is the arc length of the path over the geometric distance between
the input and the output locations of the channel. Typical values for the tortuosity
are measured experimentally from cellular imaging. The work in [122] cites values
between κ = 1.55 and κ = 1.65 in the human adult brain. The work in [123] cites
values between κ = 2 and κ = 3, and the work in [123], mentions that the tortuosity
can be as high as κ = 9 in crowded protein-loaded environments.
• The free fluid coefficient DZ is the translational diffusion coefficient of the antibodies
in the fluid, which is calculated using the result in (168).
It is noted that extracellular transport may also be subject to protein binding [124], in
which case, the model of the following section could supplement the binding of antibodies
with gels and ECM proteins. In fact, the non-specific binding equilibrium constant in the
ECM KE can be calculated from the non-specific binding energy ∆GE, which is calculated
















Figure 46. Parameters of the MC-ADDS extrallelular transport model.
the computation of the specific binding energy ∆G between the antibody and the antigens








where ∆GE is the non-specific binding free energy between the antibody and the ECM
proteins. For simplicity, we assume that the environment around the blood vessel is homo-
geneous, but, technically, the different heterogeneous layers of cell types around the blood
vessels could be accounted for by cascading the impulse response for each layer from the
plasma to the target diseased cells, based on their own tortuosity and porosity.
6.5 ADDS Antigen Binding Channel Model
In this section, we derive the characteristic function pB of the MC-ADDS Antigen Binding
Channel, as a function of the geometry and charge of the antibody, and the number of
antigens in the surface of the diseased cells. This function allows to obtain the distribution
of the ADDS antigen-antibody density at the surface of the cell y(t) as a function of the
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ADDS extracellular concentration xE(t) as follows:
y(t) = pBxE(t) . (176)











where Cag is the concentration of antigens on the surface of the diseased cells, and T is the
temperature. In the following, we derive the expression for the antigen-antibody binding
free energy ∆G, the binding probability, and the kinetic rates of the antibodies in reac-
tion with other proteins including extracellular matrix proteins and antigens. The antigen-
antibody binding free energy ∆G is calculated as follows [125]:
∆G = G+ −G− , (178)













S m,n + Vm,n + Em,n
)
, (179)
where M is the total number of beads in the antigen, N is the total number of beads in the
antibody, m and n are the indices of the beads, S m,n is the pair solvent free energy for two
beads m and n, Vm,n is the pair van der Waals energy for two beads m and n, Em,n is the
pair electrostatic potential for the two beads m and n. The equation in (179) consists of
the addition of the total energies for the antibody and the antigen, each taken individually,
where the first sum is the free energy for the individual antibody, and the second sum is the






S m,n + Vm,n + Em,n
)
, (180)
where S m,n is the pair solvent free energy for two beads m and n, Vm,n is the pair van der
Waals energy for two beads m and n, Em,n is the pair electrostatic potential for two beads m
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and n. The equation in (180) consists of the free energy of the antigen-antibody compound
joined together. The PDB database provides the antigen-antibody bead coordinates in their
joined state, therefore the bound free energy is directly computable from the database.
The pair energies used in the expressions of the unbound and bound free energies, in
(179) and (180), respectively are expressed as follows:














where qm is the charge on the bead m, qn is the charge on the bead n, ε0 is the free
space permittivity, ε is the dielectric constant of interstitial fluid, and fm,n is given by:
fm,n =
√
R2m,n + ρmρne−gm,n , (182)
where Rm,n is the distance between two elements m and n, ρn and ρm are respectively





This model is based on the generalized Born salvation free energy [126] which is an
approximation of the solution to the Poisson-Boltzmann equation.





 2ρmρnR2m,n − (ρm + ρn)2 + 2ρmρnR2m,n − (ρm − ρn)2 + ln
R2m,n − (ρm + ρn)2R2m,n − (ρm − ρn)2
 ,
(184)
where A is the Hamaker coefficient [127] which depends on the properties of the
material, and Rm,n is the center-to-center distance between two beads m and n.






where qm is the charge on the bead m, qn is the charge on the bead n, and ε is the
dielectric constant of interstitial fluid.
Finally, based on the structure data of the antigen and antibody from the PDB, namely
the charges {qn; n = 1 . . . M + N}, the radii {ρn; n = 1 . . . M + N}, the beads center-to-center
distances
{
Rm,n; m, n = 1 . . . M + N
}
, the medium parameters {A, ε} we have derived the re-
lationship between the ADDS antigen-antibody density at the surface of the cell y(t) and
the ADDS extracellular concentration xE(t) as expressed in (176) and (177).
6.6 COMSOL® Multiphysics Simulation
In this section, we present the simulation scheme used to validate the MC-ADDS model in
a realistic 3D environment. COMSOL® Multiphysics is a finite-element modeling (FEM)
software package which helps to set up complex 3D simulations involving different physi-
cal laws and models. In the interest to accurately capture the complexity of MC-ADDS sys-
tems, COMSOL® is used here to simulate two important physical laws involved in the prop-
agation of antibodies. First, the fluid dynamics (Sec. 6.6.1) provide the time-varying blood
velocity field in the blood vessels. Second, the advection-diffusion physics (Sec. 6.6.2) pro-
vide the time-varying concentration of the antibodies transported in an anisotropic manner
through the blood vessels and their surrounding tissues. By combining these two physical
laws, COMSOL® provides a realistic reference model for the spatio-temporal evolution of
the antibody through the body.
6.6.1 COMSOL® Fluid Dynamics
The blood flow is simulated by COMSOL fluid dynamics simulations to predict the blood
velocity field in the tridimensional coordinates inside the blood vessels. The blood flow
is important since it is the main driving force transporting antibodies throughout the body.
This realistic simulation is utilized to demonstrate that the assumption of uniform blood
velocity in each blood vessel is valid for the analytical model. The uniform blood velocity
allowed us to derive the simple expressions of time-varying impulse responses.
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The COMSOL® fluid dynamics is based on the Navier-Stokes equation. Blood is sup-
posed to be an incompressible fluid in laminar flow with a density ρ = 1060 kg ·m−3 and a





+ v · ∇v
)
= −∇p + f , (186)
where p is the blood pressure, v is the blood velocity, ρ denotes the blood density, ∇ is the
vector differential operator, η is the fluid viscosity, and f represents forces applies by the
blood vessel walls.
The geometry of the blood vessels network is presented in Fig. 47. The networks con-
sists of 9 curved blood vessels. The 3D data was obtained from the COMSOL® simulation
library and scaled down by a 100 factor to have the typical size of arterioles. The dimen-
sions of the blood vessels are given in Table 4.The blood vessels are surrounded by elastic
vascular walls and muscles that apply stress on the surface of the blood vessels. The out-
lets and inlets of the blood vessel network are assumed to be open with a predefined blood
pressure. The objective of the simulation is to verify that the MC analytical model prop-
erly predicts the diffusion through the walls and the diffusion along the radial dimension
by comparing the end-to-end impulse response with the concentration at the output of the
COMSOL simulated network given an initial concentration at the inlet of the network. The
surrounding tissue is simulated as a thin diffusion layer in COMSOL with a porosity of
1.6.
The boundary conditions for COMSOL® fluid dynamics consist of the time-varying
pressure applied at the inlets and outlets of the blood vessel network. The pressure at a
vessel i is denoted by pi(t) where t is the time-variable. The heartbeat period is supposed
to be constant and equal to 1s. The function pi(t) is expressed as follows:
pi(t) = pi,0 sin(πt) 0 ≤ t ≤ 0.5 s
pi(t) = pi,0 (1.5 − 0.5 cos(−2π(0.5 − t))) 0.5 ≤ t ≤ 1 s
(187)
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Table 3. Numerical values of the blood pressure at the inlets and outlets of the blood vessels network.
i 0 1 2 3 4 5
pi,0 11208 11148 11148 11148 11148 11148
Table 4. Physiological lengths and radii of the blood vessels.
Vessels V1 V2 V3 V4 V5 V6 V7 V8 V9
Length [mm] 81 17 16 18 11 14 17 11 6
Radius [mm] 2.8 2.5 2.8 2.5 2.8 2.5 2.8 2.5 2.8
where pi,0 are pressure constants in (Pa) for which the numerical values are available in
Table 3.
6.6.2 COMSOL® Advection-Diffusion
The COMSOL® advection-diffusion physics are modeled using the time-varying advection-
diffusion equation in different domains of the simulated geometry. The geometry consists
of two domains, namely the blood vessels and the ECM that surrounds it. Each domain is
denoted by the index i. The advection-diffusion equation is expressed as follows:
∂c
∂t
= ∇ · (D∇c) − ∇ · (~vc) + KVc , (188)
where ci is the antibody concentration in the domain i, Di is the diffusion coefficient or
matrix in the domain i and v is the blood velocity calculated from the COMSOL® fluid dy-
namics physics, KV is the non-specific binding equilibrium constant between the antibody
and the blood.
Between two domains, there is a molecular flux discontinuity, expressed by the follow-
ing equation:

−n · Di = DiD j (ci − c j)
−n · D j = DiD j (c j − ci) ,
(189)
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where Di and D j are the diffusion coefficients or matrices for the domains i and j respec-
tively, ci and ci are the antibody concentrations in the domains i and j respectively, and n is
the unit vector normal to the surface boundary delimiting the two domains i and j.
The following equation describes the initial concentration antibodies at the time t = 0:





C0 x ≥ x0 and z ≤ z0
c0(x, y, z) = 0 otherwise ,
(190)
where σ0 = 0.25 mm, C0 = 1 mol · L−1, and σ0 = 0.35 mm, x0 = 50 mm, and z is the third
Cartesian axis as shown in Fig. 47. A Gaussian function is used to have a smooth impulse,
which helps to avoid numerical problems.
The inlets and outlets of the blood vessel network are assumed as open extremities,
which is expressed by the following equation:
n · D∇c = 0 . (191)
The anisotropic diffusion matrix is defined in the curvilinear coordinates along the axis of
the blood vessels.
Finally, the equations in (188), (189), (190), and (191) are applied to the geometry of
the vascular channel in Fig. 47. COMSOL® calculates the concentration c(x, y, z, t) of the
antibodies in the Cartesian coordinates (x, y, z, ) and time t.
6.7 Numerical Results
In this section, we show numerical results which compare the MC-ADDS analytical model
with a finite-element methods simulation model in a realistic 3D geometry and show the
significance of anisotropy. COMSOL® was used to simulate the propagation of antibodies
using the complete advection-diffusion equation in a 3D setting, and the effect of anisotropy
on the impulse response of the system was evaluated.
Fig. 48 compares the mathematical model, derived in (161) and (162) from Sec. 6.3,
from the MC-ADDS paradigm incorporating the effect of anisotropy and the complete 3D
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Figure 47. COMSOL® simulation of ADDS propagation in the vascular channel.
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Figure 48. Validation of the analytical impulse response with COMSOL simulation results.
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Figure 49. MC Vascular Channel impulse responses for different radial diffusion coefficient DR.
simulation with COMSOL® on one blood artery. The translational and radial diffusion co-
efficients, calculated based on the bead model, have been used in both COMSOL® and the
MC-ADDS model. An excellent agreement between the two results is shown in the figure.
This is to our knowledge the first work to validate through FEM the anisotropic transport
of molecules undergoing advection and diffusion. The anisotropic diffusion coefficient was
specified in COMSOL® in matrix form in the cartesian coordinates, where the x and y rep-
resented the radial diffusion, and z represents the translational diffusion. The results show
that MC anisotropic model will allow taking into account realistic diffusion environments
that occur in biology.
Fig. 49 illustrates how the normalized impulse response from (162) presented in Sec. 6.3,
varies highly depending on the radial diffusion coefficient. For a fixed translational dif-
fusion coefficient, the radial diffusion coefficient was varied from DR = 10−7 m2/s to
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Figure 50. Translational diffusion coefficient and rotational diffusion coefficients as functions of the
angle between antibody arms.
DR = 10−4 m2/s. The numerical evaluations of the MC-ADDS extracellular impulse re-
sponse for these different values show that the anisotropic transport due to a radial diffusion
that is different from translational diffusion can have an important effect on the transport of
antibodies. It can be seen that the impulse response is attenuated exponentially as a func-
tion of the radial diffusion coefficient. Therefore, radial diffusion coefficient is a critical
parameter for the computational and numerical evaluation of MC-ADDS systems.
Fig. 50 shows the dependence of the anisotropic diffusion parameters on the angle be-
tween the arms of the antibody given by (168). from Sec. 6.3.2. In this figure, our objective
is to quantify the effect of changing the shape of the antibody on the diffusion parameters.
The bead model of the antibody illustrated in Fig. 45 at Sec. 6.5 has been considered, and
we have varied the angle between the two long arms of the antibody from −30 degrees to
30 degrees, and we have plotted the rotational diffusion coefficient DΘ and the translational
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Figure 51. Numerical evaluation of the MC-ADDS end-to-end response.
diffusion coefficient DZ for these different shapes. Note that the change in shape can have
a considerable effect on these two diffusion coefficient in a similar way. The more the
molecule resembles a rectangular shape the higher the diffusion coefficient is, and the more
the molecule resembles a spherical shape, the lower is the diffusion coefficient. This can
be explained by the fact that a spherical shape maximizes the contact surface area of the
antibodies, which causes more collisions, and therefore a higher diffusion coefficient due
to Brownian motion.
Fig. 51 shows the effect of the different kinetic processes on the MC-ADDS end-to-end
response by cascading the impulse responses of the different transport and kinetic pro-
cesses through (161) . The end-to-end impulse response is calculated for three different
sets of parameters, each corresponding to either the color red, green, or blue, i.e. the end-
to-end impulse response h1(t) is for DZ = 10−8 m2/s, DE = 10−9 m2/s, Cag = 0.01 mol/m2,
and ∆G = 5 kJ ·mol−1, the end-to-end impulse response h2(t) is for DZ = 5 · 10−8 m2/s,
DE = 0.5 · 10−9 m2/s, Cag = 0.05 mol/m2, and ∆G = 5 kJ ·mol−1, and the end-to-end
impulse response h3(t) is for DZ = 10−7 m2/s, DE = 10−8 m2/s, Cag = 0.1 mol/m2, and the
antigen-antibody binding free energy ∆G = 5 kJ ·mol−1 obtained through (178) in Sec. 6.5.
For the vascular impulse response, we observe that increasing the translation diffusion co-
efficient of the antibodies increases the delay and the dispersion of the impulse response.
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The figures for the vascular and extracellular impulse response are normalized with re-
gard to the maximum value of the impulse responses. The vascular impulse response hV(t)
shows some periodic sharp drops due to the periodicity of the heartbeat. For the extracellu-
lar impulse response hE(t), at a fixed association and dissociation kinetic set of parameters,
the extracellular impulse response shows increased delay but decreased dispersion, due to
the interplay of kinetic and diffusion parameters in the ECM. For the binding probability
function pB, we see that the concentration of antigens in the surface of the cells is a de-
termining factor for the binding rate, and the higher the binding energy, the lower is the
binding probability. This is explained by the fact that a high binding probability is more
likely if the required energy for the antibody-antigen binding is low. The end-to-end im-
pulse responses use the average values for the binding probability. The figure shows that
the binding probability for these specific numerical values is the most significant factor in
the end-to-end impulse response, and that although the vascular and extracellular parame-
ters are very dissimilar for the green and blue end-to-end impulse response, the difference
in the binding probability makes the two end-to-end impulse responses mostly the same.
MC-ADDS systems are remarkably complex due to the interplay of different kinetic
and transport processes. The MC modeling approach allows capturing all the important
kinetic parameters in a simple analytical expression and combining them together. The
MC-ADDS approach makes it possible to evaluate numerically the effect of each of these
kinetic parameters as well as the geometry of the disease and the physiology of the patient.
Fig. 51 has shown that diffusion in the vascular space can exhibit a trend that is opposite
to the one in the extracellular space. This means that values for the diffusion coefficient
that are beneficial for the transport in the vascular channel may be detrimental in the ex-
tracellular channel. Therefore, there is a trade-off value for the diffusion coefficient that
improves transport in the vascular channel without sacrificing the transport in the extracel-
lular transport. This is important for appropriate engineering the diffusion properties of the
antibodies. The figure also shows the importance of the binding parameters, which remain
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the most critical barrier for the efficiency of ADDS. The numerical evaluation of these im-
pulse responses and functions does not require important computational resources, which
makes the optimization of MC-ADDS for a specific clinical scenario very tractable using
this approach.
6.8 Conclusions
The Molecular Communication (MC) framework was used as an abstraction of antibody-
mediated Drug Delivery Systems (ADDS), which is one of the therapeutic methods at the
forefront of pharmacological research. The proposed MC model is based on the biophysi-
cal equations which govern antibody transport and kinetics in the human body. Analytical
expressions of the impulse responses and drug delivery probabilities for the vascular trans-
port, propagation in the ECM, and antigen binding were derived to mathematically capture
ADDS. The transport and antigen-binding kinetics of ADDS are predicted based on the
geometry of the human body, and the shape and electrochemical structure of the antibody-
antigen compound.
The aim is to provide a novel model for ADDS based directly on the chemical and
structural information about the antibody molecule. Based on the geometry and the charge
of the ADDS constituting elements, we have derived the transport and binding parame-
ters of the ADDS based on the theory of anisotropic diffusion and the thermodynamics of
antibody-antigen interactions.
The derived MC model is based on the recent advances in mass transport theory to pro-
vide an analytical solution to the problem of ADDS transport. In the frame of the current,
often over-complicated models of system biology, the proposed MC approach models the
complex behavior of ADDS with a straight-forward model. Using the MC paradigm, the
ADDS transport from the point of injection to the interior of a cell has been abstracted as a
cascade of MC channels, each characterized by an analytical impulse response. The MC-
ADDS model studies the ADDS transport in the blood vessels, in the ECM, and through the
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ligand binding. Compared with existing models, the majority of the systems parameters are
directly related to the physiology, instead of using empirical values that involve statistical
estimations from experiments.
There are several important issues that remain to be investigated on the modeling of
ADDS systems. First, an optimization framework should be devised to take advantage of
the possibilities offered by the MC approach. Second, the interference from the immune
system and the endocrine system should be added to the model as a feedback process to
improve the targeting of the disease. Finally, the toxicity of ADDS should be quantified
mathematically in this framework.
The MC-ADDS model allowed determining the parts of the human body which in-
fluence the efficiency of the drug delivery, and the ADDS molecule parameters that are
critical to overcome the obstacles posed by these limiting parts. Moreover, the MC model
showed how the shape and electrochemical structure simultaneously affects the transport
and antigen-binding kinetics of the ADDS. Finally, the validation of the MC-ADDS model
against finite-element simulations in a realistic 3D geometry has shown that the model is a
good approximation for the anisotropic advection-diffusion in the complex geometry of the
body. This analytical model can be readily used to predict, design, and optimize advanced





Molecular communication (MC) is a novel communication paradigm where the transfer of
molecules is abstracted as a transfer of information. It has promised to have a wide range
of applications particularly in the biomedical field. In this thesis, the potential of the MC
paradigm is harnessed to model an important area of biomedical engineering that is the
modeling of drug delivery systems (DDS). The suitability of the MC paradigm comes from
a direct identification between the elements of a communication system and the elements
of a DDS. In fact, the injection of particles can be viewed as the transmission part of a
communication scheme, the propagation of particles as the communication channel, and
the delivery of particles as the reception part of the communication scheme. However, the
reality is that under this simplifying system view lies an important complexity in terms of
the governing physics of particle emission, propagation, and delivery. As examples, the
particles are carried by the blood flow governed by the Navier-Stokes equation, delivered
to tissues with porous material properties, and reacts according to stochastic properties. In
this thesis, a unifying framework is provided to model DDS as a communication system.
The framework is analytical, and compared with alternative methods for studying DDS’s
such as finite-element simulation and kinetic Monte-Carlo simulation.
The objectives of this thesis are as follows. First, we devise a system model that enables
the prediction of time and space evolution of drug propagation in the cardiovascular system.
The system model is based on a one-dimensional reduction of Navier-Stokes equations, the
advection-diffusion equation through Taylor dispersion, conservation laws, and topological
properties of the cardiovascular system. The system model is linked with the classical
measurements used in classical DDS systems such as pharmacokinetics and biodistribution.
Second, we develop a model to study the performance of a DDS through the concept of
information theoretical capacity. After evaluating the properties of noise in a DDS as well
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as the constraints that limits it, the information theoretical capacity of a DDS is defined and
used to measure the success of a DDS. Third, antibody-mediated DDS are considered in the
MC framework. We propose modifications to the basic framework in order to capture the
peculiarities of antibody-antigen dynamics. This enables to study the end-to-end response
of an antibody-mediated DDS.
Chapter 3 is devoted to present a molecular communication system model for particu-
late drug delivery systems. The main contributions are as follows:
• We define the basic elements of system modeling approach of particulate drug de-
livery systems using molecular communication, which consist of the topology of the
cardiovascular system, the drug injection, the drug delivery rate, the drug propagation
channel, and the blood velocity network.
• We model the blood velocity in every blood vessel of the cardiovascular system
through the definition of a blood velocity network. The calculation of the blood
velocity is based on a one-dimensional simplification of the network of blood vessels
and an analogy with transmission line networks for large and small arteries. The in-
puts to the blood velocity network are the topology (lengths and arrangement of the
blood vessels), the cardiac inflow, and the index of the target artery.
• We model the evolution of the drug concentration using harmonic transfer matrices
(HTM). Given the fact that the blood velocity is time-varying, a drug propagation
network is defined as a composition of HTMs with a equivalent linear periodically
time-varying (LPTV) link or node. The time-varying impulse response for a blood
vessel is analytically derived given the blood velocity, the length, and the radius of
the blood vessels. The HTM’s are combined using basic arithmetic rules.
Through the results of this novel approach in modeling particulate drug delivery sys-
tems, we learn that molecular communication provides a low-complexity and physiology-
based modeling framework for this type of systems. This opens up the possibility to study
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optimization techniques for particulate DDSs which could allow a careful selection of the
location of injection and drug injection profile with the goal of obtaining a desired drug de-
livery profile at a targeted site while minimizing the drug presence in the rest of the cardio-
vascular system. In addition, the models developed in this research work could potentially
serve to investigate novel communication techniques for Intra-Body Communication (IBC)
networks.
Chapter 4 is devoted to the noise and capacity analysis of particulate drug delivery
systems. The main contributions are as follows:
• We present an end-to-end system model of particulate drug delivery systems that in-
cludes not only the drug propagation but also the drug emission process and the drug
reception process. The drug emission process is characterized with several design
parameters and constraints and the drug reception process is derived based on the
interaction of blood flow with the binding of drug particles.
• We show that the noise in a particulate drug delivery system can be modeled through
an inhomogeneous Poisson process which is a function of the drug propagations
time-varying impulse response and the probability of drug reception. The results
stems from identifying the advection-diffusion equation with a Fokker-Planck equa-
tion describing the motion of one particle traveling through the several compartments
of the cardiovascular system.
• We compare the results of analytical noise model with the results of kinetic Monte-
Carlo simulations of drug particle propagation.
• We define the capacity in a particulate drug delivery systems as the maximum mutual
information between the drug injection rate and the drug reception rate. We prove
that the capacity of a particulate drug delivery systems is limited by several factors.
These include the distance, the characteristics of the emission device, and the blood
flow condition in the target location.
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Through the results of the noise and capacity analysis of particulate drug delivery sys-
tems, we establish the first work to propose the use of information theory in PDDS design.
Other works were mainly based on deterministic and probabilistic analysis of the long-
term and steady-state drug distribution throughout the body. Our information-theoretical
approach can be applied to put into use high precision nanomedicine delivery, in contrast
with traditional medicine where the drug injection is not optimized with respect to the body
variabilities such as the blood flow, the ligand-binding kinetics, and their interaction.
Chapter 5 is devoted to pharmacokinetic modeling using molecular communication.
The main contributions are as follows
• We describe the several processes that a drug particle may undergo during the propa-
gation in the human body. These include absorption, adsorption, reaction, diffusion,
and advection. We define parameters for each of these processes.
• We study the performance of a particulate drug delivery system through the analytical
definition of the path loss and the delay. These two measures are related to the
pharmacokinetics and biodistribution of a drug particle.
• We model biodistribution through the novel molecular communication-based paradigm.
We present formulas for directly calculating the amount of drug particles that effec-
tively attain their target under several system conditions.
• We present a method to optimize the drug injection in order to obtain a desired a drug
reception rate through the discretization of the time-varying impulse response of the
system.
• We compare the results of the analytical molecular communication frameworks with
the results of the finite-element-based COMSOL simulations.
Through the results of this pharmacokinetic modeling approach, we learn that the MC
abstraction allows to obtain an analytical pharmacokinetic model that accounts for various
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physicochemical processes in the particle propagation, and takes into account the impact
of cardiovascular diseases. By stemming from the pharmacokinetic model, we proposed
to use communication engineering metrics to estimate the drug biodistribution at the deliv-
ery location, while analytical expressions are obtained to estimate the drug accumulation
in the rest of the body. We have favorably compared our pharmacokinetic model with
multiphysics finite-element simulations of the drug propagation in the arterial system, and
provided numerical results for the drug biodistribution in different scenarios. We also pro-
posed a procedure to optimize the drug injection rate according to a desired drug deliv-
ery rate through the pharmacokinetic model when the injection location and delivery are
known.
Chapter 6 is devoted to present a molecular communication system model for antibody-
mediated drug delivery systems. The main contributions are as follows
• We present a system model that links the intrinsic properties of antibody-antigen
compounds with their molecular communication parameters.
• We analytically derive impulse responses for the propagation in the extracellular ma-
trix.
• We derive the end-to-end time-varying impulse response linking the emission of
antibody-mediated drugs with their specific binding to antigens located at the tar-
get site.
Through the results of this modeling framework of antibody-mediated drug delivery
systems, we learn that the MC-ADDS model enables the determination of the parts of the
human body which influence the efficiency of the drug delivery, and the ADDS molecule
parameters that are critical to overcome the obstacles posed by these limiting parts. More-
over, the MC model showed how the shape and electrochemical structure simultaneously
affects the transport and antigen-binding kinetics of the ADDS. Finally, the validation of
the MC-ADDS model against finite-element simulations in a realistic 3D geometry has
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shown that the model is a good approximation for the anisotropic advection-diffusion in
the complex geometry of the body. This analytical model can be readily used to predict,
design, and optimize advanced drug delivery systems in a versatile and accurate manner,
and to simulate sophisticated therapeutic scenarios.
We propose several future direction to extend on this work. First, to develop channel
coding techniques inspired by the naturally-occurring biological quality check of drug de-
livery agents. Second, to study the ability of drug delivery systems to target several types
of antigens simultaneously as a multiple-input multiple-output system. Third, to develop
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lanta, USA, in 2012, and the Diplôme d’Ingénieur in Telecommunications and Networks
from Institut National Polytechnique de Toulouse, France, in 2011. During 2011, he was
a physical-layer Engineer at Alcatel-Lucent, Antwerp, Belgium. In Summer 2014, he was
a guest research scholar at the Nano Communication Center (NCC) at Tampere Univer-
sity of Technology, and during 2015, he was a fellow of the Research Council of Norway
at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway.
His research interests include nanoscale biologically-inspired communications, and drug
delivery systems. He joined the BWN lab of the School of Electrical and Computer Engi-
neering, Georgia Institute of Technology, Atlanta, as a Ph.D. student in January 2012. His
research interests are in nanoscale biologically-inspired communications and drug delivery
systems.
165
SUMMARY
166
